網頁

醫藥 - 中美健康峰會競賽說明會7/24

View this email in your browser

HOW TO ACCESS CHINA'S HEALTHCARE MARKET
Still putting down random keywords in Google or seeking unknown opportunities in pitching competitions?

You are offered a face-to-face chance with policymakers, business professionals, and successful cross-border entrepreneurs of China’s healthcare industry. 
10+ presidents from AAA hospitals in China
&
Director of Alibaba Health Research Institute
(Healthcare platform attached to Alibaba Group)

The U.S.-China Health Summit is an organization aiming at advancing global health by promoting the exchange of knowledge, ideas and experiences among current and future health sector leaders from China, the U.S., and other countries. 


DATE
July 24th (Tuesday), 2018 | 6:00-8:00 p.m. (EST.)
(Dinner Included)


 LOCATION
One Broadway, 5th floor, Venture Café, Cambridge, MA 02142
 
                                                                    

肝性脑病/自闭症专题讲座

ACMES ACMESBoston 4天前


肝性脑病/自闭症专题讲座





及 --春天送你一首诗 --诗歌朗诵

肝性脑病/自闭症专题讲座



本次活动由ACMES、CYPN等多个学会联合呈现,邀请了ACMES的孔学军主席与胡克勤副主席带来自闭症与肝性脑病两个话题的专题讲座,讲座结束后还有精彩的“春天带来一首诗”诗歌朗诵。期待您的参与!



与会信息
6月16号,周六,下午1:00 - 4:00
Jimmy Fund Audiorium
450 Brookline Ave Boston MA02215

1:00-2:30pm:
 “Hepatic Encephalopathy: The Pathway to Quality Care” by Keqin Hu, MD
“The management of ASD related medical issues and co-morbidities” by Xuejun Kong, MD
2:30-4:00pm:
Songs in Spring






讲座嘉宾

The management of ASD related medical issues and co-morbidities” by Xuejun Kong, MD
Xue-Jun (June) Kong, M.D. Dr. Kong is Principal Investigator at Martinos Center, Director of Synapse Autism Program, Mass General Hospital, Harvard Medical School. She leads her Autism research team, the projects involve ASD microbiome and genomic study, biomarkers, autonomic dysfunction, eye-tracking, and brain imaging, non-invasive brain stimulation, drug clinical trials, aiming better understanding the etiology, early detection and screening, clinical subgrouping, evidence based and target treatments of ASD. She proposed and modified ASD primary care model and extensive medical evaluation protocol, and East meets West approaches for ASD. In addition, she chairs American Chinese Medical Exchange Society, International Medicine Transformation (IMT) Initiative, and To Cure Autism Institute, she is on staff at Beth Israel Deaconess Medical Center as attending physician of Internal Medicine, she also serves as Editor-in-Chief of “North American Journal of Medicine & Science” and “North American Journal of Medicine & Health”.  Dr.Kong published more than 30 peer reviewed articles and 6 autism special issues, translated “Frontiers in Autism Research -New Horizons for Diagnosis and Treatment” and “Autism Revolution” published by People’s Medical Publishing House and she has been an international speaker. She leads several ongoing ASD research projects and international collaborations beside her clinical and educational activities.

“Hepatic Encephalopathy: The Pathway to Quality Care” by Keqin Hu, MD
Keqin Hu, MD, the Director of Hepatology Services and Professor of Clinical Medicine at UCI School of Medicine. Dr. Hu received his medical education and training in Tongji Medical University, China. He become Board Certified in Internal Medicine in US after his residency at Huntington Memorial Hospital, Pasadena, and completed a fellowship in Hepatology at the USC Liver Unit. Dr. Hu has a long-standing research interest in both basic and clinical research of viral hepatitis B and C, and primary liver cancer. Dr. Hu’s current clinical research focuses on understanding how hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is associated with fatty infiltrates in the liver and disease progression, and how viral hepatitis B and C are associated with liver cancer. As an active clinical investigator, Dr. Hu participates in several important clinical trials that tests new treatments for hepatitis B and C. Currently, his laboratory focuses on searching new chemoprevention of liver cancer. Dr. Hu has co-authored more than 100 research papers, book chapters, and review articles, including publications in Proc. Natl. Acad. Sci. USA, Journal of Clinical Investigation, and Hepatology. Dr. Hu serves as an associate editor for several medical journals.

药明生物宣布投资6000万美元在美国新建生产基地

药明生物国际化战略再下一城
首次在美国布局生物制药生产基地

美国马萨诸塞州伍斯特市,中国上海,2018611——全球领先的开放式生物技术平台公司药明生物(WuXi Biologics, 2269.HK)今日宣布,公司计划投资6,000万美元(约合3.8亿人民币)在美国马萨诸塞州伍斯特市(隶属波士顿大都会区)新建现代化生物制药临床样品和商业化生产基地,并创造约150个工作岗位。

这是药明生物在全球范围布局的第十一个生产基地(药明生物十一厂),也是药明生物首次在美国新建生产基地,同时也是公司继爱尔兰、新加坡后投资建设的第三个海外生产基地。

药明生物为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,其使命是加快和转变生物制药发现、开发及生产,造福全球患者。

即将开建的药明生物美国基地将继续采用全球领先的一次性生物反应器,并率先应用“新一代生物制药生产技术”(连续生产工艺)开展商业化生产,致力于成为全球领先的生物制药“未来工厂”。该基地总产能将达到4,500升,包括22,000升流加细胞培养反应器与1500升灌流工艺生物反应器,基地建成后将拥有生物工艺开发实验室,并同时具备临床样品生产和小规模商业化生产的能力。此项目的推进得到了马萨诸塞州政府、伍斯特商业发展局(WBDC)和麻省生命科学中心(MLSC)的大力支持。

“马萨诸塞州拥有技术领先的公司、顶尖的学术机构和充满竞争力的人才,已经形成全球最具活力的生命科学创新生态系统之一。”马萨诸塞州州长查理·贝克(Charlie Baker)先生说,“我们很高兴药明生物选择在马萨诸塞州进行战略布局,更多企业的投资和快速发展将共同构建更加完整的创新生态系统。”

“这几天在伍斯特市与药明生物管理层的会见交流,让我深信他们将对这里的生命科学产业做出巨大贡献。”马萨诸塞州副州长卡琳·波利托(Karyn Polito)女士表示,“我们很高兴为伍斯特市生物医药产业园的发展而努力,我们将继续为各个领域的合作伙伴提供支持。”

“伍斯特市正在打造全新的生物医药产业园区,我们热烈欢迎药明生物成为首家选择入驻于此的企业。”伍斯特市政执政官Edward M. Augustus, Jr.先生表示,“作为全球生物医药市场中地位日益攀升的投资目的地,伍斯特市十分期待新园区的正式开幕,同时帮助药明生物的首个美国生产基地顺利落成。”

“我们很高兴药明生物选择了美国马萨诸塞州,更重要的是选择了伍斯特市。在马萨诸塞州贝克-波利托政府和伍斯特市政府的支持下,我们通过巨大努力最终促成了此项目成功落地。对伍斯特市而言,今天又是一个重要的日子。”伍斯特商业发展局总裁兼首席执行官Craig L. Blais先生表示。

麻省生命科学中心(MLSC)总裁兼首席执行官特拉维斯·麦克瑞迪(Travis McCready)先生表示,“我们很高兴见证药明生物在美国伍斯特市布局生产基地这一重大里程碑。药明生物全球领先的生物制药专业技术和能力将进一步巩固这里的生命科学创新生态系统,帮助马萨诸塞州的生物制药公司更迅速高效地开发创新疗法。我们将继续为此项目的顺利完成而努力。”

“波士顿大都会区是公认的世界生命科学领域的创新聚集地,药明生物的美国新基地在公司国际化战略中具有至关重要的作用,有助于确保公司生产的符合最高质量标准生物药,通过健全强大的供应链网络,造福全球患者。非常感谢美国马萨诸塞州各界人士对我们的大力支持,相信在大家共同的努力下,这个振奋人心的项目将迅速得到推进。”药明生物董事长李革博士表示。

药明生物首席执行官陈智胜博士表示:“我们非常高兴能在美国伍斯特市投建公司在美国的第一个生产基地,公司众多重要合作伙伴距离此基地车程仅2小时。新基地将有助于满足药明生物日益增长的生物制药开发及生产需求,从而更好地帮助当地合作伙伴加速生物药开发进程。药明生物致力于打造全球生物制药领域更宽、更广、更深的生物制药能力和技术平台,赋能当地及全球合作伙伴。”

关于药明生物

药明生物作为一家香港上市公司,是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,帮助任何人、任何公司发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。如需更多信息,请访问:www.wuxibiologics.com.cn

WUXI BIOLOGICS TO INVEST $60 MILLION TO ESTABLISH A BIOLOGICS PRODUCTION FACILITY IN THE UNITED STATES

WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States
– WuXi Biologics’ first overseas site in the United States
2018/06/11
WORCESTER, MA and SHANGHAI, June 11, 2018 – WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility (MFG11).
WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
This state-of-the-art “facility of the future” will be built upon the novel approach that WuXi Biologics has pioneered in deploying single-use bioreactors. It is also designed to run continuous bioprocessing, a next-generation manufacturing technology to be implemented in America for the first time. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing. This facility will handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.
The new manufacturing facility supported by the Government of Massachusetts, the Worcester Business Development Corporation (WBDC) and the Massachusetts Life Sciences Center (MLSC), is the Company’s first overseas site in the United States, as well as the third outside China subsequent to Ireland and Singapore new sites.
“Massachusetts is home to one of the world’s most dynamic life sciences ecosystems, with leading companies, top-tier academic institutions, and a globally-competitive workforce,” said Massachusetts Governor Charlie Baker. “We are enriched when companies grow and invest here and are pleased to welcome WuXi Biologics’ expansion.”
“Having met WuXi Biologics’ leaders during their recent trip to Worcester, I am confident that they will contribute greatly to the city’s life sciences industry,” said Ms. Karyn Polito, Lieutenant Governor of Massachusetts. “I have been pleased to work on the development of Worcester Biomanufacturing Park and our Administration remains committed to supporting our public private partnership.”
“The City of Worcester is thrilled to welcome WuXi Biologics as its first tenant to the new Biomanufacturing Park,” said Worcester City Manager, Edward M. Augustus Jr.. “As a growing destination in the global biomedical market, the city looks forward to officially opening this impressive campus and is eager to host WuXi Biologics in their first US manufacturing facility.”
“We are delighted that WuXi Biologics has chosen the United States, Massachusetts, but most importantly Worcester. We competed very hard for this one and we prevailed. The Baker / Polito Administration and the City of Worcester stepped up to make this possible. Another great day for Worcester,” said Mr. Craig L. Blais, President and CEO of WBDC.
“We are excited to reach this important milestone on developing WuXi Biologics’ first US bio-manufacturing facility and to announce their intention to move to Worcester,” said Mr. Travis McCready, President and CEO of MLSC. “WuXi Biologics brings a global biologics manufacturing expertise that will enhance our life sciences ecosystem and help Massachusetts biopharma companies develop novel therapies quickly and efficiently. We look forward to continuing to work to finalize this project.”
“Metropolitan Boston is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global bio-manufacturing network to ensure that biologics are manufactured at the highest quality and within a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. We believe we can quickly push forward this exciting project,” said Dr. Ge Li, Chairman of WuXi Biologics.
Dr. Chris Chen, CEO of WuXi Biologics, added, “The new site will undoubtedly meet WuXi Biologics’ growing need for biologics development and manufacturing in the near future. Many partners of WuXi Biologics are located within two hours of this new site. We are all very excited to initiate our first US site to enable local companies and expedite biologics development in the United States. We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

药明康德领投Insilico Medicine战略融资,用人工智能加速新药研发

药明康德 药明康德 Yesterday
▎药明康德/报道

药明康德领投Insilico Medicine战略融资,利用新一代人工智能加速新药研发

该战略融资由药明康德风险投资基金领投,蘭亭投资(淡马锡控股子公司)、BOLD Capital和Juvenescence跟投。

马里兰州巴尔的摩市和中国上海2018年6月11日电 /美通社/ -- 2018年6月11日,美国新一代人工智能公司Insilico Medicine宣布完成由药明康德风险投资基金领投的新一轮战略融资。Insilico Medicine总部位于马里兰州巴尔的摩市,专注于将深度学习等新一代人工智能技术应用于靶点识别、药物发现以及抗衰老研究。本轮战略投资建立在Insilico Medicine基于生成对抗网络(Generative Adversarial Networks, “GAN”)和强化学习(Reinforcement Learning, “RL”)等人工智能技术开发的药物发现流程成功获得实验验证的基础上,并旨在将Insilico Medicine的先进的人工智能技术与药明康德强大的实验能力紧密结合。


本轮融资由药明康德风险投资基金领投,其它投资人包括淡马锡控股旗下的蘭亭投资,和由Peter Diamandis创立的主要投资快速成长型高科技公司的BOLD Capital。作为Insilico Medicine在药物发现领域的合作伙伴,专注于开发延长寿命技术的Juvenescence也参与了此次投资。

Insilico Medicine创始人兼首席执行官Alex Zhavoronkov博士说:“药明康德是全球领先的药物和医疗器械研发开放式能力和技术平台公司,拥有大批专注于解决制药领域最复杂问题的顶尖合成和药物化学家及生物学家。我们很荣幸能够与药明康德以及其他在药物发现和人工智能领域拥有深厚专业知识的国际知名投资者合作。”

这笔投资旨在支持Insilico Medicine采用新一代机器学习技术研发新的药物候选分子,并进一步增强该公司发现生物标志物的能力。


药明康德董事长兼首席执行官李革博士评论说:“我们与Insilico Medicine拥有共同的愿景,都相信人工智能和机器学习将提高临床前实验的成功率并优化新药研发的流程。我们对Insilico Medicine的新一代人工智能技术印象深刻,并将与之密切合作,结合药明康德强大的研究能力将这一技术提升到一个新的水平,从而更好地为制药行业赋能,服务。”

此次投资源自于药明康德风险投资基金与研究服务部门的共同努力。两部门一直以来通力协作,致力于在全球范围内投资具有颠覆性技术的公司并与他们展开合作。

药明康德首席财务官兼首席投资官胡正国先生表示:“对Insilico Medicine的战略投资将我们的合作伙伴关系带入到新的层次,通过将我们自身的研发能力和Insilico Medicine的AI技术更紧密地整合,我们可以更好地服务整个生物制药行业。我们一直在寻求能加速药物研发过程的人工智能技术。Insilico Medicine最吸引我们的是他们的技术能力及其应用的广度,包含从使用新一代人工智能技术进行靶点鉴定和小分子生成,到区块链技术和抗衰老研究等领域。”

药明康德简介
药明康德(603259, SH)是一家国际领先的开放式能力与技术平台公司,为全球制药、生物技术以及医疗器械等领域提供从药物发现、开发到市场化的全方位一体化的实验室研发和生产服务。本着以研究为首任,以客户为中心的宗旨,药明康德通过高性价比、高效率的服务平台帮助全球客户缩短药物及医疗器械研发周期、降低研发成本。药明康德平台涵括小分子药物研发及生产、细胞疗法与基因疗法研发生产、医疗器械测试等,正承载着来自全球30多个国家的近3000多家创新合作伙伴的数千个研发创新项目,致力于将最新和最好的医药和健康产品带给全球病患,实现“让天下没有难做的药,难治的病”的梦想。

蘭亭投资简介
蘭亭投资是淡马锡控股的全资子公司。蘭亭投资是一家位于新加坡的投资机构,专注于在北亚的私募股权投资。

BOLD Capital Partners简介
BOLD Capital Partners (“BOLD”) 是一家风险投资公司,主要投资目标为早期阶段和成长型科技公司。 BOLD对能够利用颠覆性技术来改造世界并为人类社会中存在的巨大挑战提供创新性解决方案的企业特别感兴趣。该投资平台利用Singularity University和Peter Diamandis ecosystem 来积极寻求并支持世界级企业家。BOLD在加利福尼亚州圣莫尼卡和帕洛阿尔托均设有办事处。

Juvenescence有限公司简介
Juvenescence有限公司是一家专注于延长人类寿命的生物技术公司。它由Jim Mellon、Greg Bailey博士、Declan Doogan博士、Anthony Chow和Alexander Pickett于2017年创立。 Juvenescence的团队由经验丰富的药物开发人员,以及众多在生命科学和药物开发方面有着成功经验的企业家组成。Juvenescence专注于开发衰老以及年龄相关疾病的疗法。

Juvenescence认为科学界最近的进展极大地提高了我们对衰老生物学的理解,并为现在开发减缓、阻止甚至逆转衰老过程的药物创造了机会。

Insilico Medicine 公司简介
Insilico Medicine是一家新兴人工智能公司,总部位于美国马里兰州巴尔的摩市约翰霍普金斯大学东校园内的新兴技术中心,现于比利时、俄罗斯、英国、台湾和韩国等地均设有研发中心。公司旨在延长人类有效寿命并希望借助他们在生物标志物发现、药物开发、药物数字化以及老龄化研究上的先进技术来优化药物研发的每一个步骤。

Insilico Medicine在全球率先运用生成对抗网路(GAN)和强化学习(RL)来开发新的药物分子,这项技术可同时运用于已知靶点的疾病以及未知靶点的疾病。除了与大公司合作开发药物之外,Insilico Medicine也同时在内部开展药物发现项目,专注于癌症、皮肤疾病、纤维化、帕金森病、阿尔兹海默病、渐冻症,糖尿病、肌肉减少症和衰老的新药开发。通过与LifeExtension.com的合作,并借助于自身先进的生物信息技术和深度学习技术,Insilico Medicine开发了一系列自然保健药物。此外,Insilico Medicine还研发了消费者脸部识别应用,比如Young.AI.。

该公司2017年被NVIDIA列为全球前五大对未来人类最具影响力的公司之一,2018年更被美国知名创投研究机构CB Insights誉为2018 全球AI人工智慧百强公司。

WuXi AppTec Leads Strategic Investment in Insilico Medicine to Accelerate Drug Discovery Using Next-Generation Artificial Intelligence





BTBA's annual symposium
Jun 2-3, 2018, Harvard University Science Center.
Boston Taiwanese Biotechnology Symposium is held by Boston Taiwanese Biotechnology Association (BTBA), a non-profit organization established by Taiwanese professionals in biology-related fields in 2012 in Boston. We strive to bridge the academics and industry gap in the U.S. and Taiwan and to meet the needs of professionals in biology-related fields.
This year, we are grateful to have Dr. David Y.H. Chang, Global Head at Roche Pharmaceuticals, Dr. Jui-Lien Huang, the Chairperson of AbProtix, Inc, and Dr. Rachel Meyers, Entrepreneur-in-Residence, Third Rock Ventures, as our keynote speakers. As usual, we will have a spectrum of different sessions to discuss potential career options in academic and industry, as well as tactics to advance our careers in the US and Taiwan. This year’s program also feathers trending topics in AI and data science in biomedicine, so that all of us can learn about the newest innovations in biotechnology.Symposim website: http://btbatw.org/2018/

Taiwan Biotech Forum: Healthcare Innovation Beyond Borders

Join us at Taiwan Bio Forum / MJNE Annual Meeting  
Early Bird Special is ending Monday!!!     

Over 250 professionals have registered.

Look who is coming. . .

Kate Merton
Head of JLABS 
Johnson & Johnson Innovation
Greg Sieczkiewicz
Chief IP Counsel
MPM Capital

In the advent of the International BIO Convention in Boston, join us for a day of healthcare and biomedical innovations at Taiwan Biotech Forum, jointly hosted by MJNE and DCB on June 3rd at the Joseph B. Martin Conference Center at Harvard Medical School. Meet and network with top leaders in biopharma, medtech, venture capital, and academia from Taiwan and around the world.

This event will feature more than 20 speakers from Sanofi Genzyme, Samsung Ventures, LEO Pharma, SR One, M Ventures, MPM Capital, F-Prime Capital, Artiman Ventures, MIT Alumni Angels, Militia Hill Ventures, and Johnson & Johnson Innovation. The audience will also hear from keynote speakers John Jorden, Executive Director, Digital Health, Amgen and Kate Merton, Head of JLABS at NYC & Boston, Johnson & Johnson Innovation.
The Monte Jade Science and Technology Association of New England (MJNE), in partner with the Development Center for Biotechnology (DCB) will hold it's annual meeting: "Taiwan Bio Forum: Healthcare Innovation Beyond Borders."

Come heard this exciting topics and network with top leaders in biopharma, venture capital, and academia from Taiwan and around the world!
  • Keynote Topic: "Venturing into the Digital Health Era"
  • Panel Discussion: "Fostering Entrepreneurship and Innovation"
  • Panel Discussion: "Building Cross-Border Partnerships"
  • Panel Discussion: "Cross-Sector Innovation Healthcare"
  • Panel Discussion: "Fostering a Robust Ecosystem"
When: 9:00AM to 5:00PM, June 3, 2018
Where: Joseph B. Martin Conference Center, Harvard Medical School
Registration: Early Bird $25 - $45, Regular $30-$50
        *Lunch and light refreshment included

Visit 
https://www.mj-ne.org/?p=533 for more details!

20th SAPA-NE Annual Conference, Cambridge, MA, 

Jun 2-3

SAPA-NE 美中药协SAPA 







Please Join Us to Discuss 
How Can We Save the Lives of
Patients, Our Family Members,
Our Neighbors, and Ourselves.

 
Overview
June 2nd
8AM – 6PM
Annual Conference
Tang Center, MIT
June 2nd
6PM – 9:30PM
20th-Anniversary Banquet
Boston Marriott Cambridge
June 3rd
9AM - 3 PM
Investment Forum
Boston Marriott Cambridge

 
Registration
1. Click "Read More(阅读原文)" at the bottom of this article;
2. Hold and extract the QR code below
3. Visit our website for registration at 
http://sapa-neweb.org/AC2018.php
    For more information, please visit 
https://sapa-neweb.org/cms/

 
Agenda
Helping Patients with Unmet Needs Through Innovation and Collaboration
June 2nd, 2018
8:00 AM – 6:00 PM
MIT, E51, Tang Center, Wong Auditorium
2 Amherst St, Cambridge, MA
8:00–9:00
Registration and Breakfast
9:00–11:55
Session 1: 
Patients with Unmet Needs Require New Treatment and Healthcare Innovation
11:55–13:00
Lunch and Exhibition
13:00–14:20
Session 2: 
Transformative Innovation Demands Novel Platforms
14:20–15:00
Coffee Break and Exhibition
15:00–16:40
Panel Forum:
Collaborations and Opportunities Across the Ocean
16:40–17:40
Session 3: 
Global Collaboration Drives Biomedical Innovation and Productivity
17:40–18:00
Closing Remark and Networking


SAPA-NE 20th Anniversary Celebration Banquet
(Biocytogen Night)
6:30 PM – 9:30 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
18:00–18:30
Networking
18:30–18:35
Welcome Remarks
18:35–19:10
Keynote Speech and Award
19:10–21:30
Dinner / Celebration


Biotech/HealthCare
Investment Forum
June 3rd, 2018
9:00 AM – 3:00 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
9:30–9:40
Opening Remark
9:40–11:20
Keynote Talks
11:20–12:00
Panel Discussion
12:00–13:00
Lunch
13:00–14:30
Roadshow Presentation
14:30–15:00
Conclusion


 
Invited Speakers
George M. Church, Ph.D.
Professor 
at Harvard & MIT
Dost Öngür, M.D.
Chief of the Psychotic Disorders Division, McLean Hospital
Shidong Jia, Ph.D.
Founder & CEO, Predicine Holdings Ltd.
Chris Garabedian
Chairman and CEO, Xontogeny
WilliamL. Fodor, Ph.D.
Acting CSO Biostage, Inc. 
Director Translational Sciences, Cell Therapy Group
Morris J. Birnbaum, M.D., Ph.D. 
SVP and CSO, Internal Medicine Research, Pfizer Inc.
Steve Yang, Ph.D.
EVP, CBO & CSO, WuXi AppTec
Yuelei Shen, Ph.D.
President and CEO,  Biocytogen Co Ltd.
Shenghong Steve Yang, Ph.D.
Manager, Sales and BD at Sino Biological US Inc.
Hong Cheng, Ph.D. & MBA  
Associate Vice President, Head of Research Strategy and Effectiveness for Global Research at Sanofi
Jin Li, Ph.D.
Chairman and CEO, HitGen
Yulian Zhang, Ph.D., MBA 
Executive Director, Kelun-Biotech Pharmaceuticals
Bill Liang, Ph.D.
CEO, CF PharmTech, Inc.
史文钊, Ph.D.
神州医疗科技股份有限公司总裁
Libing Yu, Ph.D.
Sr. Vice President, Business Development, Viva Biotech
Wenseng Wendy Pan, J.D. & Ph.D.
Partner, Sidley Austin LLP.

Ken Li, Ph.D.
Managing Partner, Yuanming Capital
Scott Zheng, MBA
Partner & CEO, SunForest Captital
Brad Loncar
CEO, Loncar Investments

 
Partners

 
Parking

Click “Read More” and Register NOW!





You are warmly welcome to join our "20th SAPA-NE Annual Conference and 20th Anniversary Celebration" at MIT/Marriott Cambridge on Sat-Sun 6/2-6/3/2018 (www.SAPA-NEweb.org) 
The theme of 20th SAPA-NE Annual Conference (Sino-American Pharmaceutical Professionals Association - New England)  is “Helping Patients with Unmet Needs through Innovation and Collaboration”. Please join us to learn and to discuss this important topic in our lives with Big Pharmaceutical Executives, Star-up Biotech Entrepreneurs, Well-known University Professors, Famous Physicians, and International Investors. We are confident that you would not only learn frontier science, grasp the latest Drug R&D trend, understand updated medical advancement, but also find the conference as a unique opportunity expand your professional network in particular with pharmaceutical/biotech and Health Care industry with Chinese origin. Hope everyone also enjoy the memorable SAPA-NE 20th Anniversary.
The Annual Conference comprises a full-day program on 6/2 Sat 9am-6pm at MIT Tang Center, Wong Auditorium at 2 Amherst St, Cambridge, MA, followed by a SAPA-NE 20th Anniversary Banquet 6:30-9:30pm at Boston Marriott Cambridge, 50 Broadway, Cambridge, MA. In addition, we will have a Biotech/HealthCare Investment Event and Special Activities at Boston Marriott Cambridge on 6/3/2018 Sunday 9am-3pm.
欢迎来波士顿参加20届新英格兰美中药协年会和20周年庆典, MIT and Marriott Cambridge, 6/2-6/3/2018. 制药公司总监,生物制药创业家, 知名学术权威,著名医学专家, 和投资巨鳄和大家一起探讨<通过创新和合作来帮助危难中的病人><Helping Patients with Unmet Needs through Innovation and Collaboration>
Registration at http://sapa-neweb.org/AC2018.php
Annual Conf Admission for both 6/2 9am-6pm and 6/3 9am-3pm, 
$25 early bird by 5/10; $30 regular by 5/25; $40 on site after 5/26
SAPA-NE 20th Anniversary Banquet, 6/2 6:30-9:30pm
$50 with limited capacity by 5/25; $60 on site after 5/26

Best regards,
20th SAPA-NE Annual Conference Organizing Committee
www.SAPA-NEweb.org

Monte Jade will host a panel discussion, focusing on the latest and hottest topic, AI in Heathcare. You are cordially invited to join us. Please let me know if you can make it and I will send you complimentary tickets. 

Attached file contains additional information about the event. Could you publish the information and provide webpage link?  Thank you!!!

Event Details are as follows:
Taiwan Bio Forum: Healthcare Innovation Beyond Borders
Date:  Sunday, June 3rd
Venue:  Joseph B. Martin Conference Center (Harvard Medical School) 
In the advent of the International BIO Convention in Boston, join us for a day of healthcare and biomedical innovations at Taiwan Bio Forum, jointly hosted by MJNE and DCB on June 3rd at the Joseph B. Martin Conference Center at Harvard Medical School. Meet and network with top leaders in biopharma, medtech, venture capital, and academia from Taiwan and around the world.
This event will feature more than 20 speakers from Sanofi Genzyme, Samsung VenturesLEO PharmaSR One, M Ventures, MPM CapitalF-Prime CapitalArtiman VenturesMIT Alumni AngelsMilitia Hill Ventures, and Johnson & Johnson Innovation. The audience will also hear from keynote speakers Michael LaRhette, President, MassChallenge and Kate Merton, Head of JLABS at NYC & Boston, Johnson & Johnson Innovation.
Click photos for Speaker’s Bio
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Herbert_Wu.png
Herbert Wu
President
DCB
https://www.mj-ne.org/wp-content/uploads/2018/04/Trains_Fong-Chin-Su.png
Fong-Chin Su
Deputy Minister
Ministry of Science and Technology
https://www.mj-ne.org/wp-content/uploads/2018/05/Mike_LaRette-300x300.png
Michael LaRhette
President
MassChallenge
https://www.mj-ne.org/wp-content/uploads/2018/05/Shen_Chen-Yang.png
Chen-Yang Shen
Chief Executive
Taiwan Biobank
https://www.mj-ne.org/wp-content/uploads/2018/05/David_Lucchino.png
David Lucchino
Chairman
MassBio
https://www.mj-ne.org/wp-content/uploads/2018/05/Trans_Johnsee-Lee.png
Johnsee Lee
Chairman
Taiwan Biotech Industry Organization
https://www.mj-ne.org/wp-content/uploads/2018/05/Shaoyu_Chang.png
Shaoyu Chang
Investment Manager
VI Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_k_merton.png
Kate Merton
Head of JLABS
Johnson & Johnson Innovation
https://www.mj-ne.org/wp-content/uploads/2018/05/Ko_Fulung.png
Fulung Ko
Chief Administrative Officer
Taipei Exchange
https://www.mj-ne.org/wp-content/uploads/2018/04/Joan-L-1024x548-300x300.png
Joan Lau
Managing Partner
Militia Hill Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_akhil-saklecha.png
Akhil Saklecha
General Partner
Artiman Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Greg-new-large.png
Greg Sieczkiewicz
Chief IP Counsel
MPM Capital
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Kevin-Chu.png
Kevin Chu
Analyst
F-Prime Capital
https://www.mj-ne.org/wp-content/uploads/2018/05/Christopher_Kim.png
Christopher Kim
Managing Partner
Novatio Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Patrick.png
Patrick DeCourcy
Principal Program Manager
Sanofi Genzyme
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Vikas.png
Vikas Goyal
Associate
SR One
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Hyuk-Jeen-Suh.png
Hyuk-Jeen Suh
Head of Investment
Samsung Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Michael_s.png
Michael Sierra
Vice President
LEO Sci. & Tech
https://www.mj-ne.org/wp-content/uploads/2018/05/Daniel_Franke.png
Daniel Franke
Analyst
M Ventures
https://www.mj-ne.org/wp-content/uploads/2018/05/Jeng-Hsin-1.png
Jeng-Shin Lee
Chief Scientific Officer
AB Biosciences
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Marry_Ann.png
Mary Ann Picard
Dir. of Operation
M2D2
https://www.mj-ne.org/wp-content/uploads/2018/05/Patrick_Rivelli.png
Patrick Rivelli
President
Savran Technologies
https://www.mj-ne.org/wp-content/uploads/2018/05/Trans_YingTam.png
Ying K. Tam
Managing Dir. of Health
MaRS Ventures
https://www.mj-ne.org/wp-content/uploads/2018/05/Joel_Berniac.png
Joel Berniac
CEO and Co-Founder
Akrivis Technologies
Technology Showcase:
Company Name
Brief Company Introduction
Speaker
ACT Genomics
​ACT Genomics is a leading CAP-accredited cancer molecular information service provider, with proprietary NGS-panels and chip-based platform, coupling with integrated medical informatics pipeline, we transform cancer treatment paradigm and support biopharma in biomarker exploration and companion diagnostic development.
Tsung-Kai Wu
Sr. Associate Director, Business Development
Mao Ying Genetech Inc. ​
Mao Ying Genetech Inc. is a bioinformatics data analytic company dedicated to providing algorithmic technologies for diagnosis and therapy of cancer.  At Mao Ying, a multi-disciplinary team – comprising medical and computer scientists as well as a marketing expert – works together to develop diagnostic biomarkers for various types of cancer.  By applying the novel Gene Expression Portrait, we have successfully identified gene markers with potential applications to diagnosis or therapy, and developed several clinically validated products in this line, including OncoDx and MetaDx for cancer diagnosis and OrganID for human organ identification.
Pei-Ing Hwang​
General Manager
ASUS Life Corporation
ASUS Life focus on the development of smart medical application. With HealthCloud and AI application as the infrastructure, ASUS Life has PhenoFinder as a distributed database for medical data, OmniCare as a medical IoT platform, and AiNurse as a virtual application in telecare, to help hospitals develop the precision medicine.
Jerry Hsu
Senior Manager
Our mission is to create patient’s virtual avatar for better visualization to serve clinical and educational needs. Through Virtual Reality, our applications allow doctors to see through patient’s body for better surgical planning or radiotherapy simulation. In the student or patient education, the interactive and immersive learning experience enables users to eliminate conceptual hurdle so they can better understand human body. In Augmented Intelligence, our goal is to advance medical intelligence through simulated visualization.
Sam Jang
CEO
Funique VR
​Funique dedicated into realizing Stereoscopic 3D VR in film industry, and creating new generation platform for viewers.
Our Medical Stereo VR System - Observing Surgeries through Stereo VR Documenting all kinds of surgeries with Funique’s 8K per eye VR solution. Combining simulation and real-time footages, it solve the problems of lack of resources. And let medical students around the world have the chance to observe some of the greatest surgeons on earth.
Chien-Hsiang Chao
Project Manager
Bio Preventive Medicine Corp.
Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company, focusing on developing novel biomarker-based diagnostics for chronic diseases and oncology. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD), which has been applied to evaluate renal effect in a phase IIIb global clinical trial, MARLINA-T2D™, sponsored by Boehringer Ingelheim. We can help in the development of drugs not only in evaluating renal efficacy but also renal safety. BPM welcomes strategic partnerships in expanding the product pipeline and technology platform for biomarker detection, as well as international partnership for commercialization.
Dave Lee
Scientist
LumiSTAR Biotechnology, Inc.
LumiSTAR Biotechnology is an expert in iPSC technology, optogenetic tools and functional indicators. There are two main applications of our technique: (1) All-optical platform incorporated with AI and machine learning for phenotypic screening, drug discovery, and toxicity testing. (2) Organs-on-chips for precision/personalized medicine.
Yu-Fen Chang, Ph.D
President
GenomeFrontier Therapeutics, Inc.
​​CAR-T cell therapy is a gene therapy in which patients’ white blood cells are genetically engineered to fight their own cancer.  Achieving more than 90% remission rate in patients with advanced blood cancers, this innovative immunotherapy offers new hope to dying children and adults with advanced blood cancers.  Though powerful in treating advanced blood cancers, conventional CAR-T is futile in fighting solid tumors due to the drawbacks and limitation imposed by the viral vectors used in CAR-T cell engineering.  GenomeFrontier is poised to change the outlook for patients with otherwise incurable advanced solid cancers by confronting this very challenge with bold solutions using our core technologies including Quantum pBAc, a revolutionized non-viral genetic system capable of loading 30 times more genes than the viral method and an innovative cell culture system designed for expending engineered CAR-T cells to a therapeutic quantity while maintaining its potency.  With these revolutionary technologies, we are developing universal super CAR-T therapies for solid cancers which are virus-free, reversible, and potent enough for treating a wide-range of cancers in a much safer fashion than the conventional CAR-T therapies.
​Chiung-Yuan Wu
CEO
Elixiron Immunotherapeutics Inc.
Elixiron Immunotherapeutics Inc. is a pre-clinical stage company focused on the development of transforming immunotherapy to treat chronic hepatitis B and cancer.  Our lead product EI001 is a fully human monoclonal antibody ready for IND-enabling studies as a potentially first-in-class curative HBV immunotherapy.  For cancer immunotherapy, we are developing therapeutic antibodies targeting tumor microenvironment to reactivate anti-tumor immunity and block cancer metastasis. Elixiron is positioned to launch our first clinical trial and deliver one additional drug candidate for clinical development in 18 months.
Hung-Kai Chen, M.D., Ph.D.
CEO
Meeting Agenda:

Agenda
08:30-09:00
Registration & Breakfast
09:00-09:15
Welcome Remarks:
‧Herbert Wu, PhD, President, Development Center for Biotechnology
‧Crystal Sung, PhD, President, Monte Jade New England
09:15-09:30
Opening Remarks by Guest of Honor:
‧Deputy Minister Fong-Chin Su, PhD, Chief Executive Officer, Taiwan Biomedical Development Board
09:30-10:00
Keynote: Powering the Future of Healthcare by Empowering Global Entrepreneurs
‧Michael LaRhette, President, MassChallenge
10:00-10:20
Taiwan Biobank for the Health of Future Generations
‧Chen-Yang Shen, PhD, Chief Executive Officer, Taiwan Biobank
10:20-10:30
Coffee Break
10:30-11:00
Startup Ecosystem Panel Discussion – “Fostering Entrepreneurship and Innovation”
‧Moderator: Herbert Wu, Development Center for Biotechnology
‧David Lucchino, Chairman of Massachusetts Biotechnology Council
‧Johnsee Lee, Chairman, Taiwan Bio Industry Organization
11:00-12:00
Technology Showcase: Precision Medicine & Digital Health
‧ACT Genomics, Mao Ying Genetech, ASUS Life Corporation, Augmented Intelligence, Funique VR Studio, Bio Preventive Medicine, Lumistar Biotechnology, GenomeFrontier Biosciences, Elixiron Immunotherapeutics
12:00-13:00
Luncheon
13:00-13:10
Welcome Remark:
‧Shaoyu Chang, Investment Manager, VI Ventures
13:10-13:50
Keynote: JJI & JLABS – Partnering Globally in Healthcare Innovation
‧Kate Merton, PhD, Head of JLABS at NYC & Boston - Johnson & Johnson Innovation
14:00-14:20
The Advantages of Taiwan's Capital Market
‧Fulung Ko, Chief Administrative Officer, Taipei Exchange (TPEx)
14:30-15:15
VC Panel Discussion - "Building Cross-Border Partnerships"
‧Moderator: Joan Lau, Managing Partner, Militia Hill Ventures
‧Akhil Saklecha, General Partner, Artiman Ventures
‧Greg Sieczkiewicz, Managing Director, Chief IP Counsel, MPM Capital
‧Christopher Kim, Managing Partner, Novatio Ventures
‧Kevin Chu, Associate, F-Prime Capital Partners
15:15-16:00
Corporate Panel Discussion - "Cross-Sector Innovations in Healthcare"
‧Moderator: Patrick DeCourcy, Principal Program Manager, Global Medical Affairs, Immunology, Sanofi Genzyme
‧Vikas Goyal, Associate, SR One
‧Hyuk-Jeen Suh, Head of Samsung Ventures East Coast
‧Michael Sierra, Vice President, LEO Science & Tech Hub
‧Alicia Irurzun Lafitte, Principal, M Ventures
16:00-16:45
Academia-Industry Panel Discussion - "Fostering a Robust Ecosystem"
‧Moderator: Jeng-Shin Lee, Chief Scientific Officer at AB Biosciences
‧Mary Ann Picard, Director of Operations, M2D2 @ UMass
‧Patrick Rivelli, Director of Life Sciences Track, MIT Alumni Angels
‧Ying Tam, Head of Healthcare, MaRS Ventures
‧Joel Berniac, President, CEO and Co-Founder, Akrivis Technologies
16:45-16:50
Closing Remarks
‧Leon Chen, Vice President, Monte Jade New England
16:50-18:00
Networking
More information:

Title: US-Taiwan Night 2018: AI in Healthcare 
Date & Time: 5:30 pm - 9 pm, June 6th
Venue: Boston Marriott Cambridge
Registration:  https://twbionight.eventbrite.com/


China Nanjing Innovation & High-Tech Industries Promotion Symposium

Dear CABA Members / Friends,
On behalf of NECINA and CABA, we invite you to be our VIP guest for China Nanjing Innovation & High-Tech Industries Promotion Symposium. It would be a wonderful opportunity to explore the business possibilities in Nanjing, which is one of the most innovative cities in China; to learn more about the advantages of doing business there, directly from the leaders of the largest healthcare and high-tech companies; and to build the key connections with hundreds of the guests that attend the event, who are entrepreneurs, industry leaders and government officials.

Date & Time: Wed, June 6, 2018 4:00 PM – 8:00 PM EDT
Location: Hyatt Regency Cambridge, Overlooking Boston - President's Ballroom, 575 Memorial Drive, Cambridge, MA 02139

Language: English & Chinese (with simultaneous interpretation)
Dinner: included
Parking: included (we will validate your parking ticket, please park in the garage of Hyatt Regency)
Dress Code: Business or Business Casual

The theme of this symposium is “Focus on Industrial Optimization & Upgrading; Build an International City of Innovation”. Mr. Lan Shaomin, the Mayor of Nanjing, will give a speech on the advantages of investment environment and technological innovation of industry in Nanjing. After the speech, arrangements will be made for meal and communication.
Nanjing is located in the intersection of the Coastal Opening Areas and the development zone of the Yangtze River Basin. It is the political, economic, scientific and educational, as well as cultural center of Jiangsu, China. It occupies an area of 6587 km2, with the population of permanent residents reaching an estimate of 8.27 million. In 2017, the GDP of Nanjing reached 185 billion dollars. Nanjing has obvious advantages in terms of scientific and technological innovation. With many top universities and colleges gathering here, the total number of talents, the incubation platform for entrepreneurship, and the number of scientific research institutes are all leading in the country. The innovation possibilities are immense!.
The Nanjing Municipal Government has launched ten policies for the construction of an “innovative city” through the promulgation of “Document No.1”. The government is planning to use financial support and market-based instruments, and to promulgate policies favoring innovation in the form of 20 billion yuan in five years, to create the best innovation environment for various types of enterprise and talents. Although there are only ten policies in “Document No. 1”, we have provided nearly 50 supporting documents and implementation methods to specify detailed regulations and supporting measures for enterprise incubation, talent introduction, housing procurement, and financial support. It can be safely said that various types of companies and different levels of talents can all find favorable terms tailored to them and substantial support.
Agenda
4:00 pm - 5:00 pm Registration & Networking
5:00 pm Welcome speech by the representative from the Chinese Consulate General in New York
5:10 pm Welcome speech by event co-host NECINA & CABA 
5:20 pm Keynote speech by Mayor Lan Shaomin
5:40 pm Introduction of the Policy Regarding Transforming Nanjing into an Innovative City with Global Influence
5:50 pm Introduction of the development progress in Jiangbei New District
6:00 pm Speeches by entrepreneur representatives
6:30 pm - 8:00 pm Dinner & Networking
Speakers and Officials from Nanjing:
- Lan Shaomin Mayor of Nanjing Municipal Government
- Weng Guojiu Secretary-General of Nanjing Municipal Government
- Liu Li Director of Nanjing Municipal Human Resources & Social Security Bureau
- Kong Qiuyun Director of Nanjing Municipal Bureau of Commerce
- Li Aijun Director of Nanjing Municipal People's Government Foreign Affairs Office
- Ding Jianhua Associate Counsel of Nanjing Municipal Science and Technology Commission
- Officials from state-level Jiangbei New District and Nanjing Development Zone
Entrepreneurs:
- Ren Jinsheng President of Jiangsu Simcere Pharmaceutical
- Qin Yinlin President of Jiangsu Carefree Pharmaceutical
- Zhang Feng President of Yoko Pharmaceutical
- Yang Shao Founder & CEO of Geneseeq Technology Inc
- Steven Ma Vice President of GenScript
- Dong Haijun CEO of PharmaBlock Sciences Inc
- Zhou Hongwei President of Hoperun Information Technology Inc


CABA/CBA 2018 Biopharma Forum - Simcere Night
Dear CABA Members and Friends,

We cordially invite you to attend at the upcoming CABA/CBA 2018 Biopharma Forum – “Simcere Night”. The event will be held at Harvard Medical School’s Joseph B. Martin Conference Center (77 Avenue Louis Pasteur, Boston, MA 02115) from 5:30 PM to 8:30 PM on Tuesday, June 5, 2018.

As non-profit organizations based in Boston and Washington DC, respectively, Chinese-American BioMedical Association (CABA) and China Biopharmaceutical Association (CBA) strive to facilitate the communication of the latest advances in biomedical research and development; to assist in the exploration of new biotech/pharmaceutical market opportunities in the US and China; and to promote member career development and community service. Since inception, CABA and CBA have evolved into some of the most active and engaging Chinese American professional organizations locally in the greater Boston and DC Area, nationwide in the US and overseas in China.

For the upcoming 2018 Biopharma Forum, we expect to have 100+ prominent executives, investors, scientists, officials from biopharmaceutical companies, leading research institutions, venture capital investors, entrepreneurs and regulatory agencies from both US and China to come together to discuss the current state and future trend of the life science industry.

美中生物醫藥協會第11屆年會暨波士頓生物醫藥論壇 5/19


🏨Boston Marriott Newton
📍2345 Commonwealth Ave, Newton, MA 02466
🕙8:00 AM to 9:00 PM on Saturday, May 19, 2018.












                 SPEAKERS            

   
Bill Fodor, PhD
Chief Scientific Officer
 Biostage 

Felix Hsu, MBA
SVP
Head of WuXi Advanced Therapies

Geoff Mckay
CEO
 Avrobio 

Birgit Schultes, PhD
VP of Immunology
 Intellia Therapeutics Inc 

Yide Alan Jiang, PhD
Chief Strategic Officer
Xtalpi Inc.

Xiaole Shirley Liu, PhD
Professor of Statistics, Biostatistics, and Computational Biology
Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health

Tong-Tong Xue, PhD
CEO of Kelun Bo-Tai Biological Company
Vice President of Kelun Pharmaceutical Research Institute

Cheryl Cui, PhD
Partner, Nest.Bio Ventures
 Venture Partner, Venture Health

Sean Fu, PhD
Vice President of Luye Global R&D
President of Luye Boston R&D LLC  

Debra Yu, MD
Managing Director, Head of Cross-Border Healthcare Investment Banking
China Renaissance

Johnson Zhang, MBA
Vice President & General Manager, Perkin Elmer APAC

John Xu, PhD, MBA
Sr Vice President of Strategic Alliance
Abpro












Agenda

8:00 am    REGISTRATION / VENDOR SHOW
9:00 am    OPENING REMARKS
                 Bo Ying, PhD, Conference Chair
9:10 am    INTRODUCTION OF CABA
                Kevin Fang, PhD, President, CABA
9:30 am    SESSION I - CELL & GENE THERAPY
 Cellframe, a Revolutionary Organ Regeneration Platform
Bill Fodor, PhD, Chief Scientific Officer, Biostage
• Title TBD
Felix Hsu, SVP, Head of WuXi Advanced Therapies
• Transforming Standard of Care via Single Dose Gene Therapy
Geoff Mckay, CEO, Avrobio
• Title TBD
Stefan Willdt, SVP, Takeda
 Title TBD
Birgit Schultes, PhD, VP of Immunology, Intellia Therapeutics Inc
12:00 pm   LUNCH AND CAREER PATH ROUND TABLE
1:00 pm    SESSION II – TRENDS IN BIOMEDICAL RESEARCH
• Creating an Effective, AI-Driven Company for Drug Development on the Cloud
Yide Alan Jiang, PhD, Chief Strategic Officer, Xtalpi Inc.
• CRISPR Screens and Big Data Mining for Precision Cancer Medicine
Xiaole Shirley Liu, PhD, Professor of Statistics, Biostatistics, and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health
 Title TBD
Tong-Tong Xue, PhD, CEO of Kelun Bo-Tai Biological Company and Vice President of Kelun Pharmaceutical Research Institute
2:30 pm    COFFEE BREAK AND VENDOR SHOW
3:00 pm    SESSION III - INVESTMENT ACROSS BORDERS
• Venture Creation of Cross-Border Life Sciences Companies
Cheryl Cui, PhD, Partner, Nest.Bio Ventures, Venture Partner, Venture Health
• Sailing Westward by China Biopharm Firms
Sean Fu, PhD, Vice President of Luye Global R&D, President of Luye Boston R&D LLC  
 Trends in Cross-Border Transactions
Debra Yu, MD, Managing Director, Head of Cross-Border Healthcare Investment Banking, China Renaissance
• From Entrepreneur to Investor: a Novel Way to Experience Inorganic Business
Johnson Zhang, MBA, Vice President & General Manager, Perkin Elmer APAC
6:00 pm    SESSION V - DINNER RECEPTION
6:00 pm    KEYNOTE
6:45 pm    CABA ANNOUNCEMENT
7:30 pm    SOCIAL AND NETWORKING











        REGISTRATION           

   
http://18annualmeetingcaba.eventdove.com(请复制此链接并在浏览器中打开)
也可点击文末“阅读原文”或长按以下图片提取二维码直达注册页面。
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

2018哈佛华人生物医学年会报道
哈佛医学院华人专家学者联合会(HMS-CSSA)经历十载春秋,已经成为哈佛医学院专家学者不可或缺的交流平台之一。一年一度的哈佛华人生物医学年会(以下简称“年会”)更是HMS-CSSA每年的重头戏。2018年5月5日,年会如期在在哈佛医学院波士顿儿童医院Folkman Auditorium举办。本次年会一共分为4个部分,内容涵盖了Development and Epigenetics(发育和表观遗传学)、Signaling Pathway(信号通路)、Cancer Biology(肿瘤生物学)和 Deciphering Protein Structure and Genome Sequence(蛋白结构解析和基因组测序),堪称是一场学术盛宴。现场的火爆程度不用赘述,单从报名满额的速度就能一瞥虚实。知识的力量是无限的,但交流的机会是有限的,为了不让赶不到会场的朋友们留下遗憾,协会还特意设立了分会场和网络直播,让知识能够更好的分享给大家。

大会现场座无虚席
主持人毛萍萍

晨光初起,协会成员和志愿者们就陆续忙碌起来,准备迎接广大学者的到来。与会者一个个入场,时钟也一步步走向开幕。在HMS-CSSA会长杨淞博士简单的致辞之后,哈佛医学院院长 George Daley 教授代表哈佛医学院向广大学者致以问候。他强调了科学对于人类健康的重大贡献,也重点强调了科学工作者们间交流和紧密合作的重要性,以及科学工作者的社会责任。
HMS-CSSA会长杨淞

开场致辞之后,哈佛医学院院长George Daley在第一个主题报告中,介绍了他带领的课题组攻克了20年来造血干细胞体外再生的难题,成功通过过表达7个转录因子将人工诱导干细胞重编程为造血干细胞的过程。该造血干细胞可以在体内自我更新并分化为红细胞和白细胞等各种血液细胞,为需要骨髓移植的患者带来了希望。
哈佛医学院院长George Daley精彩演讲

会议第二位报告人是来自加州大学圣迭戈分校的付向东教授,他大家介绍了他实验室开发的用于从全基因组水平研究RNA和染色质相互作用的Grid-seq技术。通过该技术他们构建了不同细胞类型的染色质结构和基因组的三维构型,并发现了一系列在启动子-增强子网络中的关键调控节点。
加州大学圣迭戈分校付向东教授和哈佛医学院张毅教授

来自Whitehead研究所的美国科学院院士Rudolf Jaenisch教授首先介绍了他们实验室开发的甲基化报告系统,通过该系统可以在单细胞的水平下通过荧光衡量某一个基因启动子区的甲基化水平。接下来,他向我们介绍了使用改造后的CRISPR系统修改FMR1基因甲基化水平的工作,该工作为治疗脆性X染色体综合症提供了新的方向。
美国科学院院士Rudolf Jaenisch教授

哈佛医学院附属波士顿儿童医院的贺熹教授向大家讲述了他实验室最近一系列研究Wnt信号通路对于动物胚胎发育调控的分子机制,特别是他们最近发现的Tiki和Notum两个新的Wnt调控蛋白,这两个蛋白通过直接对Wnt蛋白的化学修饰来调控Wnt通路的活性。
波士顿儿童医院贺熹教授和王大之教授

William Pu教授来自哈佛医学院附属波士顿儿童医院,他生动地为大家介绍了“heart-on-a-chip”,这个技术是利用工程学手段将心肌细胞固定在芯片,并且可以模拟心脏功能特点。他们组利用该工具研究了包括Barth综合症和心律失常等心脏相关疾病的致病机制并筛选了可能的治疗药物。
波士顿儿童医院 William Pu教授

赵瑾(Jean Zhao)教授阐述了她对于结合靶向药物和目前迅速崛起的免疫疗法在癌症治疗中的最新发现及独到见解。她的研究显示对细胞周期蛋白依赖性激酶CDK4/6的抑制可增强肿瘤细胞的抗原呈递,并增加肿瘤内T细胞浸润,同时减少调节性T细胞(T-regs)。她同时向我们展示了联合使用p110beta 和 PD-1抑制剂在前列腺癌中的显著抗癌效果及相关最新发现。
丹娜法伯癌症研究院赵瑾(Jean Zhao)教授和祁军教授

来自哈佛医学院附属Beth Israel Deaconess医学中心的魏文毅教授为我们介绍了S6K1的最长可变剪切体p85在癌症中的重要作用。他实验室最近发现p85作为一种癌细胞分泌蛋白,可以在细胞系和小鼠模型中促进癌细胞的生长和转移。

 

Beth Israel Deaconess医学中心魏文毅教授

Nathanael Gray博士分享了一种新的靶向治疗癌症的策略,通过双功能小分子借用细胞自身的泛素化降解系统,以及以此技术为基础的dTAG技术,精准的定点降解靶标蛋白,来达到癌症治疗的目的。同时他们发现使用降解技术可以有效提高药物选择性,在CDK9的降解工作中他们完美解决了CDK9和CDK家族其他蛋白的选择性问题,为靶向治疗提供了新的机会。

 

丹娜法伯癌症研究院Nathanael Gray教授

王家槐教授从结构生物学的视角为我们阐释了神经生长因子Netrin-1与Draxin与神经受体的相互作用机制。这两个神经生长因子分别与同一神经受体DCC相互作用会引发吸引与排斥两种不同的反应。通过对三组复合物的X射线晶体结构研究及相关的神经生物学研究,揭示了通过 DCC-Draxin-Netrin-1-DCC 搭建起的桥梁形成神经细胞接触与生长的分子机制。
哈佛医学院王家槐老师和刘小乐教授

大会最后由美国国家科学院,国家医学院和文理科学院院士谢晓亮教授以生动幽默的演讲回顾了自己在哈佛大学二十年的科研经历。从早期的单分子酶学,到近期的单细胞全基因组学,谢晓亮教授向大家介绍了他在基础科研和临床应用两方面的重要工作成果。报告最后,他还详细阐述了他的研究组在单细胞三维基因组结构和单细胞转录调控模块领域的最新研究成果。谢晓亮教授的这些研究不但对于理解生物中心法则的运作方式有重要贡献,而且还极大地促进了包括产前筛查等人类健康领域的发展。谢晓亮教授将于近期赴北京大学全职工作,他此次和大家分享的科研和人生经历无疑为在座的年轻学者们提供了最为宝贵的经验。
三院院士谢晓亮教授

最后是2018年哈佛华人生命医学优秀学术奖颁奖典礼。涌金集团特别赞助了本年度学术奖的奖金,以激励哈佛的年轻学者们。 经过激烈的竞争,十二位在哈佛工作的优秀学者获得今年的学术奖。哈佛医学院刘小乐教授和谢晓亮教授为获奖者颁发了证书与奖金,以嘉奖他们在多个生物医学领域的出色成果。
2018年涌金哈佛华人生命医学优秀学术奖颁奖典礼

在热烈的掌声中,年会也落下帷幕。学术的宴席虽然会散场,但相信知识的延伸就像直线一样没有终点。这也是HMS-CSSA举办年会的意义,希望在这条直线上留下印记,能够让学者们驻足交流。从2010年第一届年会以来,HMS-CSSA就秉承着自由开放的原则,让每个人都能感受到学术的魅力。这也是为什么每次都有众多学术带头人前来分享,让年会成为中美生命科学和医学领域的重要学术会议之一的原因。学术无国界,思想无界限,希望哈佛华人生物医学年会能够越办越好,更好的为广大学者们服务!
2018哈佛华人生物医学年会组织者合影


撰稿:黄岳,岳宏,蔡文青,曹婵,周慡,段松伟

摄影:黄岳,杜广延

Harvard Chinese Life Science Annual Symposium 2018
May 5th, 2018
Folkman Auditorium, Enders Building, Boston Children’s Hospital320 Longwood Ave, Boston, MA 02115
Organizing Committee
Harvard Medical School - Chinese Scientists & Scholars Association(HMS-CSSA)
Song Yang, Qiong Ye, Linchang Huang, Wenqing Cai, Wei Li, Bin Li, Xiaoqing Wang, Shuxi Qiao, Hong Yue, Jingyu Peng, Yue Zhang, Xianrui Yang, Miao Liu, Chan Cao, Yiming Zhou, An Xiao, Yang Zhang, Yue Huang, Lijie Xing, Mohui Wei, Shengqing Gu, Tao Wang, Xiaofeng Li, Zhengnian Li, Hui Liu, Jiye Liu, Junlin Guo, Pingping Mao, Su Wang, Shuang Zhou, Jinmiao Chen, Songwei Duan, Yanan Qi
Organizing Committee Advisors
Jianzhu Chen, Professor, Massachusetts Institute of Technology
Chuan He, Professor, University of Chicago
Xi He, Professor, Boston Children’s Hospital, Harvard Medical School
Zhigang He, Professor, Boston Children’s Hospital, Harvard Medical School
Frank Hu, Professor, Harvard T.H.Chan School of Public Health 
Xiaole Shirley Liu, Professor, Dana-Farber Cancer Institute / Harvard T.H.Chan School of Public Health 
Hongbo Luo, Associate Professor, Harvard Medical School
William Pu, Professor, Boston Children’s Hospital, Harvard Medical School
Yang Shi, Professor, Boston Children’s Hospital, Harvard Medical School
Jiping Wang, Assistant Professor, Brigham and Women’s Hospital, Harvard Medical School
Hao Wu, Professor, Boston Children’s Hospital, Harvard Medical School
Yingzi Yang, Professor, Harvard School of Dental Medicine
Junying Yuan, Professor, Harvard Medical School
Yi Zhang, Professor, Boston Children’s Hospital, Harvard Medical School
Jean Zhao, Professor, Dana-Farber Cancer Institute, Harvard Medical School
Invited Speakers
George Daley, MD, PhDHarvard Medical School, Boston Children’s Hospital
Dr. George Q. Daley seeks to translate insights in stem cell biology into improved therapies for genetic and malignant diseases. Important research contributions from his laboratory include the creation of customized stem cells to treat genetic immune deficiency in a mouse model (together with Rudolf Jaenisch), the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008). As a graduate student working with Nobel Laureate Dr. David Baltimore, Dr. Daley demonstrated that the BCR/ABL oncogene induces chronic myeloid leukemia (CML) in a mouse model, which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley’s recent studies have clarified mechanisms of Gleevec resistance and informed novel combination chemotherapeutic regimens.
Dr. Daley received his bachelor's degree magna cum laude from Harvard University (1982), a Ph.D. in biology from MIT (1989), and the M.D. from Harvard Medical School, where he was one of twelve individuals in the school’s history to be awarded the degree summa cum laude (1991). He served as Chief Resident in Internal Medicine at the Massachusetts General Hospital (94-95) and is currently a staff physician in Hematology/Oncology at the Children's Hospital and the Dana Farber Cancer Institute, and a member of the Hematology Division of the Brigham and Women’s Hospital in Boston. He has been elected the National Academy of Medicine(NAM), the American Society for Clinical Investigation, the American Association of Physicians, and the American Pediatric Societies, and is a fellow of the American Academy of Arts and Sciences (AAAS) and the American Association for the Advancement of Science.
  
Xiang-Dong Fu, PhDDepartment of Cellular and Molecular Medicine, University of California, San Diego
Dr. Fu’s laboratory is interested in molecular and cell biology of RNA metabolism and regulation in higher eukaryotic cells. Current research interests in the Fu lab include the regulation of alternative splicing, functional RNA elements in mammalian genomes, transcription/splicing coupling, nuclear architecture, and cellular reprogramming. Dr. Fu was a major contributor for co-discovery of SR proteins, a family of RNA binding proteins involved in constitutive and alternative pre-mRNA processing. His laboratory was the first to identify a family of kinases specific for SR proteins and demonstrated that these kinases are critical for transducing external and intracellular signals to regulate alternative splicing in the nucleus. Dr. Fu's group elucidated a series of regulatory mechanisms for splice site selection in mammalian cells and developed multiple key technologies for high throughput analysis of gene expression, mRNA isoforms, and genomic interactions. Dr. Fu's current research is focused on integrated regulation of gene expression at transcriptional and post-transcriptional levels. Dr. Fu's contribution to biomedical science has been recognized by selection for the Searle Scholar award (1994) and the Leukemia and Lymphoma Society Scholar award (1997) and election to Fellow of American Association for the Advancement of Science (2010).
Dr. Fu is a Professor of Cellular and Molecular Medicine at University of California, San Diego. Dr. Fu received his MS degree in Virology from Wuhan University, China in 1982, PhD degree in Biochemistry from Case Western Reserve University in 1988 (via the CUSBEA program), and postdoctoral training at Harvard from 1988 to 1992. Dr. Fu joined the faculty of University of California, San Diego in 1992 (Assistant Professor, 1992-1998; Associate Professor, 1998 to 2002; and Full Professor, 2002-present).

Rudolf Jaenisch, PhD
Founding Member of Whitehead InstituteDepartment of Biology, MIT
Dr. Jaenisch lab’s expertise is in epigenetics, reprogramming and stem cells. Dr. Jaenisch began his research career as a pioneer making transgenic mice, some of which have produced important advances in understanding cancer, neurological and connective tissue diseases, and developmental abnormalities. These methods have been used to explore basic questions such as the role of DNA modification, genomic imprinting, X chromosome inactivation, nuclear cloning, and, most recently, the nature of stem cells. In addition, using mice as a model and a technique called “altered nuclear transfer,” Dr. Jaenisch has demonstrated that it is possible to procure embryonic stem cells without harming a viable embryo. More recently he has demonstrated that somatic cells can be reprogrammed in vitro to pluripotent ES-like cells and that these cells are suitable to correct both genetic and induced defects in mice by transplantation therapy. Using this technique for turning skin cells into stem cells, the lab has been able to cure mice of sickle cell anemia -- the first direct proof that these easily obtained cells can reverse an inherited disease.
Dr. Jaenisch is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He has been granted numerous awards from organizations across the world. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer and neurological diseases. Dr. Jaenisch received his doctorate in medicine from the University of Munich in 1967. He became a postdoc at the Max Planck Institute in Munich, studying bacteriophages. He left Germany in 1970 for research positions at Princeton University, Fox Chase Institute for Cancer Research and the Salk Institute. He returned to Germany in 1977 to become the head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg. He arrived at MIT in 1984. He participated in the 2005 science conference on human cloning at the United Nations and serves on the science advisory boards of the Genetics Policy Institute and Stemgent.

Xi He, PhDBoston Children’s Hospital, Harvard Medical School
Dr. He’s laboratory seeks to understand the molecular basis of cell-to-cell communication, and how this communication regulates embryonic and neural development in vertebrates. Dr. He is also interested in learning how defective regulation of cell communication causes human cancers and diseases. In particular, Dr. He is investigating signaling mechanisms employed by secreted growth factors of the Wnt family, which play critical roles in establishing the anterior-posterior axis of the embryo and underlie the formation of head versus trunk regions during early embryogenesis. Wnt signaling pathways are also pivotal in the development of human cancers--as several key Wnt signaling components are encoded by human oncogenes or tumor suppressor genes--and in the pathogenesis of many human diseases, such as osteoporosis and degenerative disorders. Dr. He aims to identify molecular components of Wnt signaling pathways and the mechanisms by which Wnt pathways are activated and governed during embryonic development and human tumorigenesis. 
Dr. He received his bachelor’s degree in engineering at Huazhong University of Science and Technology (HUST), Wuhan, China, and Ph.D. in Dr. Michael G. Rosenfeld’s lab at University of California, San Diego (UCSD). After his postdoctoral training with Dr. Harold Varmus at National Cancer Institute (NCI), Dr. He became an Assistant Professor at Boston Children’s Hospital in 1997. He was promoted to professor in 2007. Dr. He was a Pew Scholar, a Klingenstein Fellow, a W. M. Keck Distinguished Young Scholar and a Leukemia and Lymphoma Society Scholar. Dr. He received the Young Investigator Award from the Society of Chinese Bioscientists in America (SCBA) in 2004, and holds a Chang Jiang Guest Professorship and 1000 Talent Plan (B) Professorship at HUST. Dr. He is an elected Fellow of American Association for the Advancement of Science and an American Cancer Society Research Professor. He has served on numerous review and advisory boards in academia and the biopharmaceutical industry in the USA, Canada, EU, UK and China.

William Pu, MDBoston Children's Hospital, Harvard Medical School
The Pu lab is interested in the regulation of gene expression and cell lineage specification in heart development, disease, and regeneration using various technologies including genetically engineered mice, conditional gene inactivation, genome-wide chromatin occupancy analysis, and RNA expression profiling. The major goals of Dr. Pu's research include: 1. To understand the transcriptional network regulating heart development and disease; 2. To understand cell lineage specification in heart development and regeneration; 3. To understand genetic contributions to congenital heart disease.
Dr. Pu received an MD from Harvard Medical School. He completed his internship, residence, and pediatric cardiology training at Boston Children’s Hospital. Dr. Pu has been an independent PI since 2004 and has an established track record of innovation in cardiovascular biology. Dr. Pu has 19 successful postdoctoral fellow “alumni”. Among those, 12 remain in academic medicine, 11 have faculty appointments, and 8 are PIs of independent research labs in Europe, North America, and China. Dr. Pu is also the contact PI of the Boston Children’s Hospital Department of Cardiology T32 training grant and the Director of Basic and Translational Cardiovascular Research for the Department of Cardiology at Boston Children’s Hospital.

Jean Zhao, PhDDana-Farber Cancer Institute, Harvard Medical School 
Dr. Zhao’s research centers on understanding kinase signaling pathways in cancer. Her laboratory has pioneered a new front for understanding signal transduction by integrating mouse genetics, chemical biology and immunology in the field of translational cancer research. Her productive and insightful work on deciphering the role of PI3-kinase isoforms and the cyclin D1-CDK4/6 pathway in cancer not only addresses important basic science questions, but also has had a significant clinical impact. By providing a mechanistic understanding of the synergies gained for targeting PI3K isoforms and CDK4/6 in combination with immune checkpoint blockade in cancer, her lab has guided the design of current clinical trials of integrating immunotherapy and targeted therapy both here at DFCI and internationally. 
Dr. Jean Zhao is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (HMS) and Dana-Farber Cancer Institute (DFCI). Dr. Zhao has been widely recognized for her innovation and excellence in the field. After obtaining her Ph.D. degree with honors from Tufts University School of Medicine in Boston, Dr. Zhao completed her postdoctoral training in the laboratory of Dr. Thomas M. Roberts at DFCI. Dr. Zhao began her independent research at HMS and DFCI in 2006. Her honors and awards include the Career Development Awards from NIH/NCI, the V Scholar Award, the Starr Foundation Award and, recently, the Outstanding Investigator Award from NIH/NCI. Dr. Zhao serves as a member on multiple scientific boards and committees, including the Executive Committee for Research and the Committee for Women Faculty at DFCI, the Steering Committee of Breast Cancer at DF/Harvard Cancer Center and the Advisory Council of the National Brain Tumor Society.

Wenyi Wei, PhDBeth Israel Deaconess Medical Center, Harvard Medical School
The major focus of research in Dr. Wei’s laboratory is aimed at understanding how APC and SCF activities contribute towards cell cycle regulation and subsequent tumor formation. More specifically, Dr. Wei is interested in elucidating the underlying mechanisms that define the oscillation of APC and SCF activity in different cell cycle phases. Currently, he is pursuing the underlying mechanisms that timely regulate APC/Cdh1 activity in different cell cycle phases. Additionally, Dr. Wei is also interested in understanding whether other layers of crosstalk between the APC and SCF complex exist. Furthermore, Dr. Wei would like to identify novel downstream targets for both APC and SCF complexes, which will help pinpoint their functions in both cell cycle control and tumor formation. To this end, Dr. Wei has developed biochemical purification approaches that would allow him to identify novel downstream targets for APC/Cdh1 and SCF/Fbw7 complexes. In addition, he is also interested in defining the tumor suppressor function of Cdh1 utilizing conditional Cdh1 knockout mice. To achieve these goals, Dr. Wei’s lab will use multidisciplinary approaches including biochemical and genetic analysis. 
Dr. Wenyi Wei received his B.A. degree from Shandong University in 1993 and then obtained his M.S. training in Chinese Academy of Science from 1993 to 1996. Afterwards Dr. Wei received his Ph.D. training in the Department of Molecular Biology, Cell Biology & Biochemistry (MCB) at Brown University and his postdoctoral training in the laboratory of Dr. William Kaelin, Jr. at DFCI and Harvard Medical School. Dr. Wei became independent from 2006 in Department Pathology at Beth Israel Deaconess Medical Center and Department of Pathology at Harvard Medical School. 


Nathanael Gray, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Dr. Nathanael Gray’s research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance. Dr. Gray has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Amongst the additional notable achievements of Dr. Gray’s research laboratory are: development of the first T790M selective EGFR inhibitors, ATP-competitive mTor inhibitor, Torin1, and its use to discover that rapamycin is an incomplete inhibitor of mTOR; development of the first inhibitors of ERK5 (BMK1), CDK7 and CDK12. 
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. In 2006, Dr. Gray returned to academia and accepted a faculty appointment at the Dana Farber Cancer Institute and Harvard Medical School in Boston. Dr. Gray’s scientific contributions have been recognized through numerous awards including the Career Award of the National Science Foundation in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011.

Jiahuai Wang, PhDDana-Farber Cancer Institute, Harvard Medical School
Dr. Wang’s lab has been focusing on structures of cell surface receptors that play critical roles in the immune system and nervous system. In collaboration with colleagues within Dana-Farber and Harvard Medical School, the Wang lab has worked out structures of a number of key immune molecules, including T cell receptors, MHC molecules, co-receptors and their interacting complexes. His group has also determined structures of many cell adhesion molecules, such as CD2, CD58, Cadherin, ICAM family members and the complexes with their interacting partners. More recently he begins to turn his interests into neuronal receptors. Most recently in collaboration with a group at EMBL, Hamburg, Dr. Wang has determined the structure of netrin-1 in complex with DCC, uncovering the molecular mechanism of netrin-1 bi-functionality, a long-standing puzzle in the neuroscience field.
Dr. Jiahuai Wang obtained his B.A from the University of Science and Technology of China in 1963 and an equivalent Ph.D. from the Beijing Biophysics Institute, Chinese Academy of Sciences in 1979. He had worked in Biophysics Institute in the period of 1963-1979. During 1979-1982, he was a visiting scholar at University of Wisconsin at Madison and at Harvard University, the Department of Biochemistry and Molecular Biology. In 1982-1988 he was back in Beijing Biophysics Institute, promoted to Associate Professor and later Professor. He served as director of Protein Crystallography Department there in 1987-1988. He was appointed as a member of National 863 Committee of Biotechnology of China in 1986-1990. He came to the United States again late in 1988 working at Harvard Medical School, the same department till 1996 before moving to Dana-Farber Cancer Institute as a Principal Investigator. In 2001, he was promoted as an Associate Professor of Pediatrics and Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Xiaoliang Sunney Xie, PhDDepartment of Chemistry and Chemical Biology, Harvard University
Dr. Xiaoliang Sunney Xie received a B.S. from Peking University in 1984, and his Ph.D. from the University of California at San Diego in 1990, followed by a short postdoctoral experience at the University of Chicago. In 1992, Xie joined Pacific Northwest National Laboratory, where he later became a Chief Scientist. In 1999, he was appointed Professor of Chemistry at Harvard University. He was the first full professor at Harvard University from the People's Republic of China since China's reform in 1978. He is currently the Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard, and the Director of Beijing Advanced Innovation Center for Genomics at Peking University.
Xie is among the first to conduct fluorescence studies of single molecules at room temperature in the early 1990s. He has made major contributions to the emergence of the field of single-molecule biophysical chemistry and its application to biology. His team also pioneered the development of coherent Raman scattering microscopy and single cell whole genome sequencing.
His honors include the Albany Prize in Medicine and Biomedical Research, the U. S. Department of Energy E. O. Lawrence Award, the Biophysical Society’s Founders Award, the National Institute of Health Director’s Pioneer Award, the Sackler Prize for Physical Sciences and the American Chemical Society’s Peter Debye Award. Xie is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He is also an honorary fellow of the Chinese Chemical Society and has received scholarly awards from China, Germany and Israel. 


2018 Harvard Chinese Life Sciences YONGJIN Distinguished Research Award Awardees

Harvard Chinese Life Sciences YONGJIN Distinguished Research Award is sponsored by Yongjin Group, which is to reward Chinese scientists whose research and discoveries were published or accepted for publication in 2017 & 2018 and well recognized by the scientific community. After tons of applications and some seriously stiff competition, we're super excited to announce that the following twelve researchers are awarded 2018 Harvard Chinese Life Sciences YONGJIN Distinguished Research Award! 
They will be awarded at the Harvard Chinese Life Science Annual Research Symposium on May 5, 2018, the symposium will take place at the Folkman Auditorium, Enders Building, Boston Children’s Hospital, 320 Longwood Ave, Boston, MA 02115.

Diamond Sponsors:
Gold Sponsors:
哈佛医学院华人专家学者联合会
Website: http://www.hms-cssa.org
微信公众号: hmscssa

Harvard Chinese Life Sciences (HCLS) YONGJIN Distinguished Research Award is sponsored by Yongjin Group, which is to reward Chinese scientists whose research and discoveries were published or accepted for publication in 2017 & 2018 and well recognized by the scientific community. After tons of applications and some seriously stiff competition, we're super excited to announce that the following twelve researchers are awarded 2018 Harvard Chinese Life Sciences YONGJIN Distinguished Research Award! 
They will be awarded at the Harvard Chinese Life Science Annual Research Symposium on May 5, 2018, the symposium will take place at the Folkman Auditorium, Enders Building, Boston Children’s Hospital, 320 Longwood Ave, Boston, MA 02115.

Chongyi Chen, Ph.D. 
Department of Chemistry and Chemical Biology, Harvard University
Dr. Chen is a postdoctoral fellow from Prof. Xiaoliang Sunney Xie's lab at Harvard University, studying single-cell genomics. He developed a single-cell whole-genome amplification (WGA) method, Linear Amplification via Transposon Insertion (LIANTI). The new method supersedes previous single-cell WGA methods in various key aspects, enabling the detection of single-cell copy-number variations genome-wide at kilobase resolution. The LIANTI method was recently published in Science (2017), with many ongoing efforts at the moment in relevant technology development, as well as scientific and clinical applications.
Publication (2017~2018):
  • Chongyi Chen*, Dong Xing*, Longzhi Tan*, Heng Li*, Guangyu Zhou, Lei Huang, X. Sunney Xie. “Single-cell Whole-genome Analyses by Linear Amplification via Transposon Insertion (LIANTI)”, Science 356, 189-194 (2017) (*co-first author)
Kangmin He, Ph.D.
Boston Children’s Hospital, Harvard Medical School
Dr. He received his Ph.D. from Peking University in 2013 and then started his postdoc training in Dr. Tom Kirchhausen’s Lab at Boston Children’s Hospital and Harvard Medical School. Currently he is a research associate at Boston Children’s Hospital and instructor at Harvard Medical School. His research is characterized by use of advanced optical-imaging microscopies to examine the cell membrane trafficking processes. Especially his current research has focused on studying the molecular mechanisms that underlie the assembly and dissemble of clathrin-coated molecular machineries using quantitative live-cell imaging techniques. 
Publication (2017~2018):
  • Kangmin He+, Robert Marsland III, Srigokul Upadhyayula, Eli Song, Song Dang, Ben Capraro, Weiming Wang, Wesley Skillern, Raphael Gaudin, Minghe Ma, Tom Kirchhausen+. Dynamics of phosphoinositide conversion in clathrin-mediated endocytic traffic. Nature (2017) 552:410-414. (+co-corresponding author)
  • Nan Li, Rong Zhao, Yahong Sun, Zi Ye, Kangmin He+, Xiaohong Fang+. Single-molecule imaging and tracking of molecular dynamics in living cells. National Science Review (2017) 4:739–760. (+co-corresponding author)
Contact Information: Kangmin.He (at) childrens.harvard.edu
Julia Joung, Ph.D. Candidate
Broad Institute of MIT and HarvardDepartment of Biological Engineering, MIT
Julia Joung is a graduate student in the lab of Feng Zhang at the Broad Institute of MIT and Harvard. She received her B.S. from Stanford University in bioengineering, where she worked in the neurobiology lab of Ben Barres on astrocyte-mediated synaptic pruning. At Stanford, she was selected for the departmental commencement speaker and for the Terman Engineering Scholastic Award. After graduation, as a research scientist at Counsyl, she helped develop a large-scale, cost-effective sequencing protocol for genetic diagnostics. In the lab of Feng Zhang, she develops CRISPR-Cas9 tools for studying long noncoding RNAs and neurological diseases.
Publication (2017~2018): 
  • Joung, J., Engreitz, J.M., Konermann, S., Abudayyeh, O.O., Verdine, V.K., Aguet, F., Gootenberg, J.S., Sanjana, N.E., Wright, J.B., Fulco, C.P., Tseng, Y.Y., Yoon, C.H., Boehm, J.S., Lander, E.S., and Zhang, F. “Genome-scale activation screen identifies a lncRNA locus regulating a gene neighborhood,” Nature, 2017.
  • Joung, J., Konermann, S., Gootenberg, J.S., Abudayyeh, O.O., Platt, R.J., Brigham, M.D., Sanjana, N.E., and Zhang, F. “Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening,” Nature Protocols, 2017.
Ying Li, Ph.D.
Department of Molecular and Cellular Biology, Harvard University
Dr. Li currently a fifth-year postdoctoral fellow in the laboratory of Prof. Catherine Dulac in the Department of Molecular and Cellular Biology, Harvard University. In 2013, she graduated from the Institute of Neuroscience, Chinese Academy of Science, Shanghai where she earned a Ph.D degree in neuroscience with Dr. Jiulin Du. Her primary interest is to understand the neural basis of social information processing in instinctive circuitry. One of her major contributions is to reveal the neural principles of social representation in the medial amygdala (MeA), a key hub of the sensory-motor transformation from chemosensory cues to instinctive behaviors in mice (Li et al., Cell, 2017). 
Publication (2017~2018):
  • Li, Y., Mathis A., Benjamin GF., Osterhout J., Ahanonu B.,Schnizter M.,Venkatesh N and Dulac C+ (2017). Neuronal representation of social information in the medial amygdala of behaving mice. Cell 171(5), 1176-1190.
Contact Information: yingli01 (at) fas.harvard.edu
Changliang Liu, Ph.D.
Department of Neurobiology, Harvard Medical School
Dr. Liu obtained his PhD from the Chinese Academy of Sciences in 2013 and has been working as a postdoc in the Department of Neurobiology at Harvard Medical School. His research is focused on molecular machinery (active zone) underlying neurotransmitter release and mechanism of dopamine signaling. He has recently identified the release sites of dopamine, which changed the long-standing dogma that dopamine transmission lacks endogenous architecture. Liu is also very interested in drug research. He has founded a biotech startup (https://cambriandiscovery.com/) aiming at developing cutting-edge new tools for drug discovery and development. 
Publication (2017~2018):
  • Changliang Liu, Lauren Kershberg, Jiexin Wang, Shirin Schneeberger, Pascal S. Kaeser, Dopamine secretion is mediated by sparse active zone-like release sites, Cell, 8 February 2018, Pages 706–718.e15 
  • Manyan Wong, Changliang Liu, Aram C.f. Roquas, Stephen Fowler, Pascal S, Kaeser, Liprin-α3 controls active zone composition, synaptic vesicle docking and exocytosis in hippocampal nerve terminals, PNAS, 2018 Feb 8. pii: 201719012 
  • Changliang Liu, Yakun Wang, Guozhang Jin, Weixing Shi, Ming Gao, Cocaine-induced locomotor sensitization associates with slow oscillatory firing of neurons in the ventral tegmental area, Sci Rep., 2018 Feb 19;8(1):3274 
  • Jiali Song, Juan Zhang, Changliang Liu, Chao Liu, Kongkai Zhu, Feifei Yang, Xigong Liu, João Paulo Figueiró Longo , Luis Alexandre Muehlmann, Ricardo Bentes Azevedo, Yu-Ying Zhang, Yuewei Guo, Cheng-Shi Jiang, Hua Zhang, Design and synthesis of pregnenolone/2-cyanoacryloyl conjugates with dual NF-κB inhibitory and anti-proliferative activities, Bioorg Med Chem Lett. 2017 Oct 15;27(20):4682-4686
Contact Information: Changliang_Liu (at) hms.harvard.edu
Nan Liu, Ph.D.
Boston Children’s Hospital, Harvard Medical School
Dr. Liu obtained his PhD in 2015 in National Institute of Biological Sciences, Beijing, where he studied the mechanism of heterchromatin spreading under the supervision of Dr. Bing Zhu. After PhD he decided to move on his study of epigenetic regulation to a defined developmental process, and he joined Dr. Stuart Orkin’s lab in 2017. Here he worked on how γ-globin is switched off during fetal to adult globin switch in blood cells. His recent finding provided a new model for this biological process, and unexpectedly, answered a longstanding question in the field raised several decades ago.
Publication (2017~2018):
  • Liu N, Hargreaves V, Zhu Q, Kurland JV, Hong J, Kim W, Sher F, Macias-Trevino C, Rogers JM, Kurita R, Nakamura Y, Yuan G-C, Bauer DE, Xu J, Bulyk ML, Orkin SH. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell 2018; 173:430-42.
Xiao (Shawn) Liu, Ph.D. 
Whitehead Institute for Biomedical Research, MIT
Dr. Liu was interested in understanding the molecular mechanisms of biological processes. His PhD study demonstrated how cell division was regulated by Polo-like kinase 1-mediated phosphorylation of diverse substrate proteins. As a postdoctoral fellow in Rudolf Jaenisch’s lab at Whitehead Institute, he developed a molecular tool for precise epigenome editing that enables the functional interrogation of individual epigenetic events. Using this tool, he demonstrated that demethylation of the hypermethylated CGG repeats at the pathological locus of FMR1 can restore FMR1 expression and rescue the electrophysiological abnormalities associated with Fragile X syndrome neurons. His career goal is to become an independent investigator in academia, and to uncover the epigenetic mechanisms that underlie brain functions and disorders at a cellular and molecular level.
Publication (2017~2018):
  • Liu, X.S., Wu, H., Krzisch, M., Wu, X., Muffat, J., Hnisz, D., Li, C., Yuan, B., Vershkov, D., Benvenisty, N., Young, R.A., and Jaenisch, R. (2018). Rescue of Fragile X syndrome by DNA methylation editing of the FMR1. Cell. 173, 1-14. 
Liang Tao, Ph.D.
Boston Children’s Hospital, Harvard Medical School
Dr. Tao received his Ph. D. degree in Biology from University of Science and Technology of China in 2010. Following a two-year postdoctoral research at Kansas University Medical Center, he joined Dr. Min Dong's lab at Harvard Medical School in 2013. He has been investigating human pathogens and host-bacteria interactions, and mainly worked on bacterial toxins in Dr. Dong’s lab. One of his major findings is the identification of frizzled proteins as epithelial receptors for Clostridium difficile toxin B, which was published on Nature in 2016. Afterwards, by collaborating with a group in UC Irvine, they also defined the molecular basis of how this toxin recognizes its receptor frizzled (Science, 2018). Along the lines of basic research, he is also keen on translating the insights and knowledge of toxins toward developing new scientific tools as well as therapeutics. In early 2018, he was promoted to the junior faculty rank of instructor at HMS. He has accepted an offer as an assistant professor in Westlake Institute for Advanced Science, and will establish an independent lab later this year.
Publication (2017~2018):
  • Chen, P.*, Tao, L.*, Wang, T., Zhang, J., He, A., Lam, K., Liu, Z., He, X., Perry, K., Dong, M., Jin, R., (2018) Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B. Science (In Press)  (* co-first authors)
  • Tao, L.*, Peng, L.*, Berntsson, RP-A., Park, S., Yu, F., Boone, C., Stenmark, P., Krupp, J., and Dong, M., (2017) Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nature Communications 8, 53. (* co-first authors)
Contact Information: liang.tao (at) childrens.harvard.edu
Jingyi Wu, Ph.D.
Broad Institute of MIT and Harvard, Mass General Hospital, Harvard Medical School
Dr. Wu earned her bachelor degree from China Agricultural University in 2012, and is conducting her Ph.D. research in the laboratory of Dr. Xie Wei in the Tsinghua University. Her thesis project is to study chromatin dynamics in early mammalian development. Using ATAC-seq and CARM, She and her colleagues have systematically revealed how open chromatin reprograms during human and mouse embryogenesis for the first time and identified the key transcription factors regulating this process. She is now doing her postdoc in Bradley Bernstein lab in Broad Institute and MGH to study the epigenetic regulation in cancer.
Publication (2017~2018):
  • Wu J*, Xu J*, Liu B* et al. & Xie W. Chromatin analysis in human early development reveals epigenetic transition during ZGA. Nature. (2018) In press (*: co-first author)
Xuhua Wang, Ph.D.
Boston Children’s Hospital, Harvard Medical School
Dr. Wang is a postdoctoral research fellow from Prof. Zhigang He’s Lab at Boston Children’s Hospital, Harvard Medical School, studying brain spinal circuit basis for motor control and developing gene and stem cell based regenerative therapy to cure spinal cord injury or stroke. His works have been recently published in Cell and Neuron. His findings have important impact on developing treatment strategies to cure spinal cord injury and stroke and studies in brain machine interface.
Publication (2017~2018):
  • Wang, X.*; Liu, Y.*; Li, X.*; Zhang, Z. *; Yang, H.; Zhang, Y.; Williams, P. R.; Alwahab, N. S. A.; Kapur, K.; Yu, B.; Ding, H.; Chen, M.; Gerfen, C. R.; Wang, K. H.; He, Z. “Deconstruction of corticospinal circuits for goal-directed motor skills” Cell, 2017, 171, 440- 445.  (*co-first author)
  • Liu, Y.*; Wang, X.*; Li, W.*; Zhang, Q.; Li, Y.; Zhang, Z.; Zhu, J.; Chen, B.; Williams, R. P.; Zhang, Y.; Yu, B.; Gu, X.; He, Z. “A sensitized IGF1 treatment restores corticospinal axon-dependent functions”, Neuron, 2017, 95, 817–833.  (*co-first author)
Jinfang Zhang, Ph.D.
Beth Israel Deaconess Medical Center, Harvard Medical School
Dr. Zhang earned his Ph.D. degree in the year of 2012 at Peking University in China. From 2013 to 2015, he received the postdoctoral research training at Beth Israel Deaconess Medical Center, Harvard Medical School. In 2015, he was promoted to the instructor at Harvard Medical School. In 2017, he received the NIH/NCI K99/R00 pathway to independence award. Currently, his research interest is exploring and developing novel effective antitumor strategies.
Publication (2017~2018):
  • Zhang J*, Bu X*, Wang H*, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ+, Sicinski P+, Wei W+. Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance. Nature. 2018 Jan. 4; 553(7686): 91-95. (*co-first author) 
  • Wan L*, Xu K*, Wei Y*, Zhang J*, Han T, Fry C, Zhang Z, Wan Y, Huang L, Yuan M, Xia W, Chang W, Huang W, Liu C, Chang Y, Liu J, Wu Y, Jin V, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W. Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Molecular Cell. 2018 Jan 18; 69(2): 279-291. (*co-first author)
  • Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q+, Zhang J+. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Letters. 2017 Jan 28; 385: 207-214. (+co-corresponding author)
Contact Information: jinfangz13 (at) icloud.com
Yiming Zhou, Ph.D.
Brigham and Women’s Hospital, Harvard Medical School
Dr. Zhou is a postdoctoral fellow at Brigham and Women’s Hospital, Harvard Medical School, and Broad Institute of MIT and Harvard. His work focuses on the calcium signaling in kidney diseases. He identified a TRPC5 channel blocker as the first ion channel-targeted therapy for progressive proteinuric kidney disease. He is expanding his research goals into harnessing the power of genomics, and particularly single cell technologies, to inform our understanding of calcium signaling in kidney, so that he may pursue targeted, precision therapies targeting calcium signaling pathways. 
Publication (2017~2018):
  • Y Zhou*, Castonguay P*, et al. A small molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models. Science 2017, 8 (6368), 1332-1336. (*: co-first author)
Sponsored by:

哈佛医学院华人专家学者联合会
Website: http://www.hms-cssa.org
微信公众号: hmscssa

HXD 2018: June 26-27th in Boston

We believe that person-centered design and innovation have the power to improve health! If you agree, then you need to be at the Health Experience Design conference!!

HXD provides a unique crossroads for a diverse community of leaders and practitioners in strategy, innovation, research, design, and technology to accelerate transformation across the health ecosystem.

Attracting over 500 visionaries, this two-day mix of inspiring presentations, workshops, and discussion will help drive real world change.

At the conference, you will hear keynotes from brilliant luminaries like Sara Holoubek, Jane Sarasohn-Kahn, Sara Wachter-Boettcher, Dr. Michael Rich and Alan Manning on hot topics from the front-lines of healthcare including ethics, designing for those in crisis, health equity, and digital addiction.

Workshops will immerse you in hands on learning experiences in Participatory Design, Transformation by Design, Designing and Measuring Engagement in Behavior Change Interventions, and Data Science and Design Strategy Variety Hour.

Conference tracks will cover exciting topics like Designing with Underserved Communities, Measuring Patient Experience, From Innovation to Execution, Navigating the Logistics and Finances of Health, Digital Interventions in Behavioral Health and Addiction, The Science of Behavior Change Design, Advancing Wellbeing, Innovation Beyond the Pill, A Patient-Centered Business, and Content Strategy & Literacy.

Register before May 4th when the early bird rate expires with code HXDPartner and save $300 off of the standard rate! http://www.hxdconf.com 

Join us for the day-long discussion with U.S. and Chinese healthcare leaders!

The 7th U.S.-China Health Summit is coming on September 15, at Harvard Medical School! Join us to hear senior managers like the Chief Health Officer of IBM Watson Health, renowned scholars from Harvard and Peking Union Medical College, as well as hospital executives and policy makers discuss important healthcare challenges and opportunities.
This is a great opportunity for those interested in the global healthcare industry. If you want to catch up with latest healthcare trends in U.S. and China, learn more about a career in healthcare, and expand your network with dedicated leaders in healthcare, or if you are just looking for opportunities to broaden your horizons regarding global issues, we sincerely invite you to the 7th U.S.-China Health Summit!

Themed “Megatrends in Health and Healthcare,” the 7th U.S.-China Health Summit will discuss:

1) the changing world and emerging health challenges;
2) megatrends in health and medical sciences and technology; 
3) megatrends in healthcare service innovation.


Confirmed speakers and their speech topics include: 
Ezra Vogel
Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
“From Deng Xiaoping to Xi Jinping: the New Era of China”
Donald Ingber
Founding Director, Harvard Wyss Institute
“Breakthrough Discoveries Cannot Change the World If They Do Not Leave the Lab”
David Blumenthal
President, Commonwealth Fund
“ObamaCare, TrumpCare, and the Future of US Healthcare” 
Yuanli Liu
Dean, Peking Union Medical College School of Public Health
“Public Health Achievements and NCD Challenges in China”
Shaoping Deng
President, 
Center of Translational Medicine, the Chinese Academy of Sciences
“China’s Comparative Advantage and Weakness in Medical Research and Translation” 
Steve Chen
Founder and CEO, 
Third-Brain Research Institute

“Supercomputers Grid for Healthcare Cloud and Brain/Cancer Research, Genetics Engineering, Precision Medicine and Cancer Immunology Therapy”
Jingwei Liu
Director of Healthcare Innovation, China Electronic Sciences Inc.
“Developing a People-Centered Active Care Model in China”
Robert Huckman
Professor of Business Administration, Harvard Business School
Making Healthcare a Consumer Product"
Jing Ma
Associate Professor,
Brigham & Women’s Hospital

Why Chinese Doctors are Unhappy? A Report From China
Arthur Kleinman
Professor of Medical Anthropology in Social Medicine, Harvard Medical School
"Mental Health in China in the Context of Global Health"
Randall Moore
President, Mercy Virtual Health
“Virtual Health"
Kyu Rhee
Vice President and Chief Health Officer, IBM Watson Health
"Future of Health is Cognitive"
Peter Juhn
Vice President and Global Head of Value-Based Partnerships, Amgen
“Value-Based Contracting"
Brent James
CTO, Intermountain Healthcare
"Strategies to Lower Costs, Improve Quality, and Engage Patients"
Bill Sibold
CEO, Sanofi Genzyme
(Speech Topic TBD)
Jack Spengler
Akira Yamaguchi Professor, Harvard T.H. Chan School of Public Health
"Cities, Climate Change & Health: A Future Not Informed by the Past"
(Speakers and topics may be subject to slight change as needed.)
More speakers are detailed on our website.

Tickets
Tickets for different groups (industry, general public and students) are now available on our Eventbrite on a first come, first served basis.
Industry tickets include VIP dinner – a unique chance to talk with Summit speakers & guests and learn more about future opportunities in Chinese healthcare market! 
If you have any questions, feel free to email us at info@uschinahealthsummit.org
and we will reach out to you shortly. We look forward to witnessing with you how U.S. and Chinese healthcare leaders are moving forward together!
About U.S.-China Health Summit

U.S.-China Health Summit (the Summit) has been dedicated to advancing global health by promoting exchange of knowledge, ideas and experiences among the current and future health sector leaders from China, the U.S. and other countries.
The annual Summit has become an important part of the U.S.-China Strategic and Economic Dialogue, as well as the People-To-People Exchange Program. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academic, policy and investment topics in 10 forums.


 2017年对全球医疗卫生事业是意义非凡的一年。中国于今年启动了“健康中国2030长期规划”,政府与民间正如火如荼地投入到医疗大健康的领域;美国的政府与民间也在医疗健康领域积极寻求变革策略。本届峰会以“大健康,大趋势”为主题,将重点探讨:

      1)全球卫生健康面临的复杂挑战
      2)健康和医学科学技术的大趋势
      3)健康和医疗服务创新大趋势

我们诚挚邀请您参与这场中美医疗界的年度盛会,共同探讨未来的健康医疗大趋势!峰会现开放注册,注册请扫描文末二维码。

部分演讲嘉宾:
Ezra Vogel
哈佛大学社会科学荣誉教授
主旨演讲
William Haseltine
ACCESS健康国际有限公司董事长兼总裁
Arthur Kleinman
哈佛医学院社会医学人类学教授
刘远立
北京协和医学院公共卫生学院院长
Mark Elliott  
哈佛大学国际事务副教务长
Kyu Rhee
IBM Watson Health副总裁兼首席卫生官
Randall Moore
Mercy Virtual Health主席
 David Blumenthal
英联邦基金会主席
Robert Huckman
哈佛商学院工商管理教授
Donald Ingber
哈佛威士研究所创始主任
Alan Trager
公私伙伴关系倡议创始人兼主任; 清华大学PPP研究中心国际比较研究中心首席专家
孙喜琢 
深圳市罗湖医院集团总院长
更多重量级嘉宾及详情请关注中美健康峰会官方网站:uschinahealthsummit.org
或点击下方“阅读原文
峰会注册请扫下方二维码:
Time:
Sep 9th (Saturday) 2017, 10am - 2pm
Location:
Dana Building 1620, Dana-Farbar Cancer Institute
450 Brookline Ave, Boston, MA 02215
Lunch will be provided

纳斯达克上市公司
中国最大的细胞治疗公司——
西比曼生物科技公司
(Cellular BioMedicine Group)
西比曼全球分布
加州 | 马里兰 | 上海 | 无锡 | 北京


Tony Liu, CEO
曾担任阿里巴巴全球副总裁
微软中国首席财务官和全球战略总经理


Yihong Yao, CSO
曾担任Medimmune/阿斯利康制药公司药物基因组学和生物信息学高级总监
雅培制药公司高级科学家
西比曼目前临床试验产品

• 美国加州政府干细胞专项支持机构(CIRM)资助开展的异体人源脂肪干细胞治疗膝骨关节炎(临床试验I/II期)
• 嵌合抗原受体T细胞疗法(CAR-T)治疗急性B淋巴细胞性白血病,非霍奇金淋巴瘤, 多发性骨髓瘤以及各种实体瘤(临床试验I/II期)

主办单位

美中生物医药协会 
哈佛大学医学院华人专家学者联合会

The 7th U.S.-China Health Summit (the Summit) is coming in September. As the organizing committee, we invite you to attend the first part of the Summit, which will be held on September 15, 2017 in Boston.
Since its inauguration in 2011, the Summit has been dedicated to promoting exchange of knowledge, ideas and experiences of healthcare leaders from the U.S., China, and other countries. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academy, policy and investment topics in 10 forums.
This year, we are still boosting that communication and collaboration. 2017 is a unique year, marking both the inception of China’s implementation of the Healthy China 2030 Plan and the beginning of President Trump’s new Administration. Since the annual Summit has been held alternately in the U.S. and China since 2011, and by tradition this year’s Summit shall be held in the U.S., this year we will have a Boston Part (Part 1) of the Summit on September 15. In addition, we will organize a Beijing Part (Part 2) of the Summit on September 23, following the Centennial Celebration of Peking Union Medical College (PUMC)
Themed “Megatrends in Health and Healthcare,” this year’s Summit will focus on: 1) the changing world and emerging health challenges; 2) megatrends in health and medical sciences and technology; and 3) megatrends in healthcare service innovation.
Confirmed keynote speakers of the Boston Part include:
  • Mark Elliott, Vice Provost for International Affair, Harvard University
  • Arthur Kleinman, Professor of Medical Anthropology in the Department of Social Medicine, Harvard Medical School
  • Yuanli Liu, Dean, PUMC School of Public Health
  • William Haseltine, Chairman and President, ACCESS Health International, Inc.
  • Ezra Vogel, Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
  • Kyu Rhee, Vice President and Chief Health Officer, IBM Watson Health
  • Randall Moore, President, Mercy Virtual Health
  • David Blumenthal, President, Commonwealth Fund
  • Xuetao Cao, President, PUMC
  • Robert Huckman, Albert J. Weatherhead III Professor of Business Administration, Harvard Business School
  • Donald Ingber, Funding Director, Harvard Wyss Institute
  • Alan TragerFounder and Director, Public-Private Partnerships Initiative; Chief Specialist, International Comparative Research, Tsinghua University Center for PPP Research (TUPPP)
The list may be subject to slight change. Tickets are sold on a first come, first served basis, and we are offering early bird discounts for registration before August 21.
For more information about this year’s or past Summit, please refer to our website: www.uschinahealthsummit.org, or email us at: info@uschinahealthsummit.org. We look forward to witnessing with you how healthcare leaders from the U.S., China, and other countries are moving forward together!


WuXi NextCODE Completes $240 Million Series B Financing
Investment from leading technology and healthcare investors will accelerate the growth of the global platform for genomic data

The global platform aims to empower institutions and individuals to realize the full value of their genomic data - to benefit human health and contribute to advancing precision medicine
SHANGHAI and CAMBRIDGE, Mass. and REYKJAVIK, Iceland, Sept. 7, 2017 /PRNewswire/ -- WuXi NextCODE, the global platform for genomic data, today announced the successful completion of a $240 million Series B financing.
The company extended and completed the Series B round with investment from a consortium led by Sequoia China and including TemasekYunfeng Capital and 3W Partners. Temasek, Yunfeng and 3W also participated in the initial Series B round in May alongside Amgen Ventures and other existing long-term investors and partners.  China Renaissance Group is the sole financial advisor to WuXi NextCODE in the latest financing round.
"The success of this financing round, which includes some of the top technology and healthcare investors worldwide, underscores the breadth and depth of confidence in our vision: to serve as the global platform for using genome data to advance global health," said Hannes Smarason, CEO of WuXi NextCODE. "We have the unique expertise and now the resources to execute on this strategy. We plan to continue to push the leading edge of technology for digitizing, managing and analyzing genomic big data, including through our pathbreaking AI, and to put it at the service of ever more enterprises, institutions, and individuals around the world."
"Genomics is an intrinsically global big data opportunity of unprecedented scale, and with breakthroughs in artificial intelligence, there will be explosive growth opportunities in the field of precision medicine," said Neil Shen, founding and managing partner of Sequoia China. "Sequoia China attaches great importance to investment in genomics and precision medicine. In leading WuXi NextCODE's latest financing round, Sequoia China is able to support the company to build out a standard platform to efficiently turn sequence data into benefits for people worldwide. This is truly where healthcare and technology meet."
"Our mission is to enable anyone to use the genome so that everyone can benefit from it," said Dr. Ge Li, chairman of WuXi NextCODE and founder and chairman of WuXi AppTec. "That is why we are building the global platform for genomic data and why we so pleased to have attracted such a stellar group of investors who not only share our vision but are uniquely positioned to support our growth. Only a platform with millions of genomes can provide the network effect and knowledge base that enable everyone to derive greater benefit, continually attracting more users, more data, and delivering ever more powerful health insights to serve people and patients everywhere."

WuXi NextCODE is using the proceeds from this round to accelerate the extension of its platform infrastructure and to bring new users and data onboard through precision medicine and diagnostics partnerships; the commercialization of its consumer solutions for the China market; and ultimately by enabling individuals to take charge of their own genomic data and deploy it to advance health and healthcare.


YHIF2017 Achieved a Great Success!

Young Health Innovators Forum (YHIF) held its 2017 Boston competition on August 5. From among 62 applicants, we selected 12 as U.S. semi-finalists to pitch their ideas. Each team presented innovative solutions to unmet needs in today’s fast-growing healthcare market, impressing our judges and the audience with how latest technologies can advance healthcare. Nonspec, MobioSense, Z Imaging and XenoTherapeutics became U.S. finalists and are invited to the final round of YHIF2017 in Beijing.
Click here to learn more about YHIF2017 teams and their innovative ideas! 

“Our minds are challenged yet inspired. We learned so much from the amazing young people this afternoon! I’d like to quote Dr. Gross, a Nobel Laureate: ‘The more we know, the more we are aware of what we know not.’”
--Olivia Ho Cheng, Board member of the U.S.-China Health Summit

Boston Taiwanese Biotechnology Symposium is held by Boston Taiwanese Biotechnology Association (BTBA), a non-profit organization established by Taiwanese professionals in biology-related fields in 2012 in Boston. We strive to bridge the academics and industry gap in the U.S. and Taiwan and to meet the needs of professionals in biology-related fields.
This year, we are honored to introduce Dr. Lily Y. Jan (Professor of UCSF; member of National Academy of Sciences and Academia Sinica) and Dr. James C. Liao (President of Academia Sinica; member of National Academy of Sciences and Academia Sinica) as our keynote speakers.
Highlights of our program include:
  • Panelists from both academia and industry to discuss the latest research, potential applications, and clinical development of “CRISPR technology” and “Immunotherapy”.
  • A new session on “Advancing your career” to learn about leadership and people skills, and how to exercise those skills and plan strategically to develop and establish a successful career in academia and industry.
  • A new session on “Commercialization of life innovation” to learn about technology transfer, the role of venture capital, and more about entrepreneurship.
  • Academic panelists from the U.S. to share their experience in research and career path in Academia.
  • Explore and build your career path in biotech or pharma by connecting with people from diverse fields.
  • Meet researchers from Academia Sinica. You may submit your CV to be considered in 1-on-1 setting.
  • Roundtable lunch with panelists
The annual meeting aims to provide platforms for interactions among young professionals, postdocs and students to share experiences and learn insight in diverse bio-related career paths.
The Summit invite you to attend the upcoming Young Health Innovators Forum 2017 (YHIF2017) Boston competition, which will be held at Harvard T.H. Chan School of Public Health on August 5 from 12:00 pm to 5:00 pm.

As an important part of the Summit, YHIF aims at helping young health innovators address unmet healthcare needs with innovative technologies and business models. This year, 12 teams will present their projects, which cover digital health, pharmacy, biotech, and other healthcare-related subjects. We will invite four finalists to Beijing to present their ideas in front of hundreds of hospital executives, pharmaceutical gurus, and investors.

We believe this is a great chance for you to catch up with latest healthcare investment hotspots, as well as meet many young healthcare professionals. You can find more details about the event on our website and get the free tickets of YHIF2017 by registering here. We look forward to seeing you this Saturday!
About U.S.-China Health Summit
The U.S.-China Health Summit is dedicated to the advancement of global health by promoting the exchange of knowledge, ideas, and experiences of healthcare leaders from the U.S., China, and other countries through high-level strategic dialogues, leadership development programs, and applied research. Click here to learn more about us.
The 7th U.S.-China Health Summit (the Summit) is coming in September. As the organizing committee, we invite you to attend the first part of the Summit, which will be held on September 15, 2017 in Boston.
Since its inauguration in 2011, the Summit has been dedicated to promoting exchange of knowledge, ideas and experiences of healthcare leaders from the U.S., China, and other countries. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academy, policy and investment topics in 10 forums.
This year, we are still boosting that communication and collaboration. 2017 is a unique year, marking both the inception of China’s implementation of the Healthy China 2030 Plan and the beginning of President Trump’s new Administration. Since the annual Summit has been held alternately in the U.S. and China since 2011, and by tradition this year’s Summit shall be held in the U.S., this year we will have a Boston Part (Part 1) of the Summit on September 15. In addition, we will organize a Beijing Part (Part 2) of the Summit on September 23, following the Centennial Celebration of Peking Union Medical College (PUMC)
Themed “Megatrends in Health and Healthcare,” this year’s Summit will focus on: 1) the changing world and emerging health challenges; 2) megatrends in health and medical sciences and technology; and 3) megatrends in healthcare service innovation. Confirmed keynote speakers of the Boston Part include:
Mark Elliott, Vice Provost for International Affair, Harvard University
Arthur Kleinman, Professor of Medical Anthropology in the Department of Social Medicine, Harvard Medical School
Ezra Vogel, Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
Robert Huckman, Albert J. Weatherhead III Professor of Business Administration, Harvard Business School
The list may be subject to slight change. Tickets are sold on a first come, first served basis, and we are offering early bird discounts for registration before August 21.
For more information about this year’s or past Summit, please refer to our website: www.uschinahealthsummit.org, or email us at: info@uschinahealthsummit.org. We look forward to witnessing with you how healthcare leaders from the U.S., China, and other countries are moving forward together

7/27: US-CHINA Healthcare Transaction Lessons

2017-07-14 Xiaoyang 斐药圈
Topic:
US-CHINA Healthcare Transaction Lessons 

Date:
July 27th, Thursday from 7:00pm to 9:00pm

On Thursday, July 27th, San Francisco Healthcare Drinks, CABS, and ChinaMed Capital will host a talk by Carey Chern, General Counsel of SciClone entitled 'Lessons Learned from US-CHINA Cross Border Healthcare Transactions'. Chinese life sciences companies and Investors (e.g., PE and venture capital firms) are interested in doing transactions with US companies, including M&A, licensing and other commercial transactions.  Carey will provide his legal perspective on US companies entering into transactions with Chinese entities.

About Carey

Carey Chern joined SciClone in October 2016 and serves as General Counsel and Corporate Secretary, as well as SciClone's Chief Compliance Officer. Prior to joining SciClone, from 2011 to 2016, Mr. Chern served in various roles at The Clorox Company covering healthcare matters. Prior to The Clorox Company, Mr. Chern served in various roles at Amgen Inc. Prior to Amgen, Mr. Chern served as an attorney in several large international law firms covering life sciences and corporate transactions matters. Mr. Chern earned a J.D. from Stanford Law School and his A.B. in Economics and Government from Harvard University.

Event Location:
1633 Old Bayshore Hwy, Suite 280, Burlingame, CA 94010.

Contact Us:
Brian Hakim: +1(415)-902-6510     
Clare Gu:+86-186-163-16925     


斐药圈(ChinaMed Capital Group)
Symposium program can be found on our website: http://btbatw.org/2017

19th SAPA-NE AC Brochure

Greetings from Conference Chair
Dear SAPA Members and Friends:
On behalf of the organizing committee, it is my great pleasure to welcome you to the 19th Annual Conference of the Sino-American Pharmaceutical Professionals Association New England (SAPA-NE). SAPA-NE is a non-profit organization founded in 1998 and currently serves more than 2000 pharmaceutical/biotech professionals. Our mission is to serve its members and foster their career development through conference/symposium/networking and to promote exchanges and collaboration across pharmaceutical/biotech industries and academics between China and the US.
Our annual conference is SAPA-NE’s most prestigious event. Every year we bring together leaders from academia and industry, investors and entrepreneurs from around the world to share the cutting-edge discovery, exciting clinical development, and experiences and trends in business and career in life sciences. The theme of this year’s conference is "Convergence: Transformation of Life Sciences in Boston".
Boston is now recognized as the epicenter of innovation for both biologics and small molecules R&D in the world. More than 400 large and small biopharmaceutical companies have established headquarters or research centers here, plus many world-leading hospitals and prestigious universities, among them are Novartis, Pfizer, Sanofi, Biogen, Merck, Astra-Zeneca, AbbVie, Bristol-Myers Squibb, Takeda, Shire, EMD Serono, J&J and Bayer etc., as well as numerous small innovative companies. It’s difficult to fathom that this healthy and thriving ecosystem has not always been here. It started almost 10 years ago deep in the financial crisis that affected global economy. The Life Science Initiative enlisted the input and resources from government agencies, industry leaders, academic institutions, venture capitalists, and law firms. What we have witnessed since is an unprecedented growth in translating research discovery into therapeutic development. The game-changing immunotherapy in cancer treatment, the potential applications of genome editing technology such as CRISPR-Cas9, are just a couple of many areas that local companies are working on. This is the golden area of life sciences innovation, and Boston is the place where it all happens.
There are multi-national pharmaceutical companies overcoming cultural and organizational challenges to locate research centers in Boston area. There are local startups successfully raising capital when the overall trend is less than ideal. There are talented scientists helping accelerate the R&D process by crossing over between academia and industry. Those are the reason behind the theme for this year’s annual conference, to celebrate what makes Boston uniquely attractive to life sciences – the convergence of all the essential elements needed for transformation. This full day event will include plenary sessions, panel discussion, and a dinner reception. Biopharma industry senior executives, Chinese returnee entrepreneurs, and other experts will share their visions on scientific innovation, high-tech entrepreneurship, new trends in R&D globalization and strategies. Local and Chinese companies will bring a variety of job opportunities and set booths to recruit talents.
This year’s annual conference dinner reception is generously supported by our Diamond Partner, Greenberg Traurig, LLC, which is celebrating its 50th Anniversary. A keynote speech titled “Convergence of Law and Biopharma” will be given by Dr. Fang Xie, co-lead of its Biotechnology and Pharmaceutical Group.
Finally, I would like to express my most sincere gratitude towards all the members of the conference organizing committee for their outstanding work and unparalleled dedication in making this event possible. I am also grateful for all our valued sponsors for their generous and continued support. Everybody is welcome to join SAPA-NE and together we build an even stronger community. Thank you!
Sincerely yours,
Larry Cai, MBA, MS.
SAPA-NE 19th Annual Conference Chair
SAPA-NE President Elect 2016-2017
Conference Program
8:00 – 9:00
Registration and Breakfast
Opening Remarks
9:00 – 9:10
Mr. Larry Cai, Conference Chair, SAPA-NE President-Elect
Hon. Deval Patrick, Governor, Massachusetts (2007-2015)
Mr. Jijun Xing, Counselor of S&T, Consulate General of P. R. China
Session 1: Cutting Edge of Biomedical Innovation in Boston
Chairs: Drs. Jun Johnny Yang, Xingfeng Bao, Kejie Li, Lin Lin, Jing Tong
9:10 – 9:45
Dr. Andy Plump, Chief Medical and Scientific Officer, Takeda
“The Future of Drug Discovery: Innovation-driven Research & Development at Takeda”
9:45 – 10:20
Dr. Richard Murray, CEO and President, Jounce Therapeutics
“Immunology meets oncology: breakthroughs in immunotherapy”
10:20 – 10:50
Coffee Break and Exhibition
10:50 – 11:25
Dr. Sven Ante “Bill” Lundberg, CSO, CRISPR Therapeutics
“Bringing CRISPR Therapeutics to the Clinic”
11:25 – 11:50
Dr. Luhan Yang, CSO, eGenesis
“Gene Editing to Transform Xenotransplantation”
11:50 – 12:10
Dr. James Yang, President/CEO of Abpro China
“Fast Road Map for Biologic R&D”
12:10 – 1:00
Lunch and Exhibition
Session 2: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Mangeng Cheng, Dapeng Chen, Haishan Li, and Bing Ma
1:00 – 1:20
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery”
1:20 – 1:40
Dr. Shidong Jia, Founder & CEO, Predicine Holdings Ltd.
“Precision medicine: clinical application of liquid biopsies in cancer”
1:40 – 2:00
Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
“Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs”
2:00 – 2:20
Ms. Jane Li, Co-founder, AF Recruiting
“Landscape of Healthcare Job Market in China”
Panel Forum: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Tianxiao Sun and QiYing Hu
2:20 – 3:20
Dr. Shaohui Huang, Zhongshan Tsuihang New District
Dr. Ruhong Jiang, Applied Stemcell
Dr. Jinbo Lee, Scilligence
Dr. John MacDougall, CrownBio
Dr. Weimin Tang, Hengrui Therapeutics Inc.
Dr. Tony Xie, Xiyu Investment Company
3:20 – 3:50
Coffee Break and Exhibition
Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences
Chairs: Mr. Larry Cai, Drs. Guiqing Liang and Jianzhu Chen
3:50 – 4:20
Dr. Lijun Wu, Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
“From Seed to Exit in 15 Months: The Delinia Story”
4:20 – 4:50
Dr. Yinxiang Wang, Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Zhejiang Betta Pharmaceuticals
“Challenges and Strategies of Innovative Drug R&D in China”
4:50 – 5:25
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
“Follow the Science and Capture the Opportunities”
5:25 – 5:30
Closing Remark: Dr. Jiang Long, President of SAPA-NE
SAPA-NE 19th Annual Conference Dinner Reception (Ticket Required)
Sponsored by Greenberg & Traurig, LLP
(Location: Samberg Conference Center, 50 Memorial Drive, Cambridge MA)
Chair: Dr. Jiang Long, President of SAPA-NE
6:00 – 6:30

6:30 – 6:35


6:35 – 6:45



6:45 – 7:00



7:00 – 7:10


7:10 – 9:00
GT HomeNetworking

Welcome Remarks
Dr. Jiang Long, President of SAPA-NE

Keynote Speech
Dr. Fang Xie, Co-lead, Global Life Science, Greenburg Traurig, LLP
“Convergence of Law and Biopharma”

SAPA-NE Cooperate Service Award/Service Award Presentations
Dr. Jiang Long and Mr. Larry Cai/ Drs. Bingli Ma, Mark Lin, Xiaotian Zhong, Min Chen

SAPA-NE High School Excellence Scholarship Presentation
Drs. Huo Li and Guiqing Liang

Dinner/Networking

Opening Remark
Session 1: Cutting Edge of Biomedical Innovation in Boston

http://www.takeda.us/images/usr/default/header_logo_ci.jpg
Andy Plump, MD, PhD Chief Medical and Scientific Officer, Takeda Pharmaceuticals
Presentation title: The Future of Drug Discovery: Innovation-driven Research & Development at Takeda





Richard Murray, Ph.D., Chief Executive Officer and President
Presentation title: Immunology meets oncology: breakthroughs in immunotherapy




Logo
Dr. Sven Ante “Bill” Lundberg, Chief Scientific Officer, CRISPR Therapeutics
Presentation title: Bringing CRISPR Therapeutics to the Clinic



http://www.egenesisbio.com/uploads/2/8/6/4/28647375/1472768483.png
LUHAN YANG, Ph.D., Co-Founder and CSO
Presentation title: “Gene Editing to Transform Xenotransplantation




James Yang, Ph.D., President and CEO, Abpro-China
Presentation title: “Fast Road Map for Biologic R&D





Session 2: Collaborations and Opportunities Across the Ocean
http://www.wuxiapptec.com/images/logo1.png
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Presentation title: Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery
http://www.predicine.org/uploads/4/6/3/9/46396713/logo-vision.png
Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd
Displaying image1.JPGPresentation title: “Precision medicine: clinical application of liquid biopsies in cancer”




Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
Presentation Title: Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs






Ms. Jane Li,
Co-founder of AF Recruiting
Presentation title: Landscape of Healthcare Job Market in China




Panel Forum: Collaborative Innovation and Partnership




Shaohui Huang, Ph.D., Business Consultant, Zhongshan Tsuihang New District; President & Co-Founder, LightEdge Technologies, Ltd.; Professor, Institute of Biophysics, Chinese Academy of Sciences







Applied StemCell
Ruhong Jiang, Ph.D.,
Co-founder, President and CEO, Applied StemCell, Inc.





Jinbo Lee, Ph.D., Co-founder and Chief Scientific Officer of Scilligence Corporation





John MacDougall, Ph.D., Director of Scientific Engagement, CrownBio




Image result for jiangsu hengrui medicine
Weimin Tang, Ph.D., Head of BD, Jiangsu Hengrui Medicine Co.





logo.png
王利春,科伦药物研究院常务副院长,国家大容量注射剂工程技术研究中心主任






Mr. Shuijiang Zhou, Founder, Xiyu Investment Company




Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences

https://atlasventure.com/wp-content/uploads/Delinia.png
Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
Presentation title: “From Seed to Exit in 15 Months: The Delinia Story”



Beijing Jacobio Pharmaceuticals Co.,Ltd
Yinxiang Wang, Ph.D., Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Betta Pharmaceuticals
Presentation title: Challenges and Strategies of Innovative Drug R&D in China




Logo
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
 Presentation title: Follow the Science and Capture the Opportunities


Dinner Reception Keynote Speech
Dinner Keynote Speaker:
Fang Xie, Ph.D.
Of Counsel, Co-lead, Global Life Sciences, Greenberg Traurig, LLP, Boston

Presentation title: The Convergence of Law and Biopharma”





Diamond Partner

https://pbs.twimg.com/profile_images/819255504463478784/7PLlkNxG.jpg

Platinum Partner

http://www.wuxiapptec.com/images/logo1.png


Media Partner

Gold Partner


http://www.predicine.org/uploads/4/6/3/9/46396713/logo-vision.png
Silver Partner

Applied StemCell https://www.bms.com/content/dam/bms/us/en-us/downloads/BMS-logo.jpg
Image result for jiangsu hengrui medicine logo.png http://www.takeda.us/images/usr/default/header_logo_ci.jpg
https://vcanbioctbblog.files.wordpress.com/2017/02/cropped-20160816015810429.jpg?w=300


Event Partner
http://www.aberjonalabs.com/images/header.jpg Achemtek
Logo Image result


Beijing Jacobio Pharmaceuticals Co.,Ltd
China CRO Company,Preclinical research services
Selleck Chemicals Logo https://www.wyzerbio.com/wiser/image/top-banner.jpg


CABA美中生物医药协会2017年会暨十周年庆典召开在即

 2017-04-11 Jo Lee CABA
“Boston BioForum 2017”
CABA10th Annual Conference
Coming Soon!!!
🏨Boston Marriott Newton
📍2345 Commonwealth Ave, Newton, MA 02466
🕙10:00 AM to 6:00 PM on Saturday, May 6, 2017.








SPEAKERS

Gordon Freeman

Professor at Harvard University

Carmen Bozic, MD
Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulatory approval of therapies in Biogen’s therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry.
Kenneth I Kaitin, Ph.D.
Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin alsoholds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel.
Ken LeClair, Ph.D.
Ken LeClair received his undergraduate degree from BowdoinCollege and a Ph.D. in Immunobiology from Yale University.
He did a postdoc at the MIT Center for Cancer Research andhad an academic appointment as Assistant Professor of Medicine in theImmunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School.
He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.
Samarth Kulkarni, Ph.D.
Samarth(Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015.  At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. 
Xinyu Weng, Ph.D.
Weng, Xinyu, Ph.D, is First Secretary of the Embassy of the People’s Republic of China to the United States of America. As the primary point ofcontact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry.
Lynn Yang, MBA
Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capitalhealthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product managerat GE Healthcare.  
Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.
Jason Fisherman, MD, MBA
Jason is an investor in medical innovation, drug developer, and company founder. He has worked to build life science companies as a managing director at the global private equity firm Advent International and subsequently as co- founder of the venture spin-out Synthesis Capital. Jason has funded more than thirty companies that have brought over ten new products to market.
James (Jianguo) Yang, Ph.D.
Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China. Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in Abbott Lab Pharma Division, MedImmune /Astra Zeneca, and Genzyme / Sanofi.

Junzhi (John) Yao, Ph.D.
Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. He joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research for cardiovascular diseases and stroke.

In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada, which has become one of the top CROs in Canada.
Hui Cai, Ph.D.
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances,and Head of PR and Corporate Communications.
Prior to WuXi, Dr. Cai spent 10 years at Johnson& Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmunediseases.








Agenda

09:00 - 10:00 am      Registration / Social and Networking
10:00 - 10:05 am      Opening Remarks, Conference Chair
10:05 - 10:15 am      Introduction of CABA, President, CABA
Featured Speaker
10:15 - 11:00 am       Kenneth I. Kaitin,Ph.D., “The Global Landscape for Pharmaceutical R&D: Current Trends -Future Opportunities”
Session I -Immunotherapy: for the Cure ofCancer
11:00 - 11:35 am       Samarth Kulkarni,Ph.D. “CRISPR-based Therapeutics:  Making it a Reality in Asian Markets”
11:35 - 12:10 pm       Ken LéClair, “Development of Cell and Gene-edited Products”
LUNCH AND VENDOR SHOW: 12:10 - 1:30 pm (LunchProvided on Site)
LUNCHOEN PRESENTATION
12:45 - 1:15 pm  TC Scientific Presentation, John Yao, "A CRO's View of the Pharma Landscape"
SESSION II – Innovation,Investment, and Entrepreneurship
1:30 - 2:05 pm          Hui Cai, Ph.D. Wuxi (TBD ,)
2:05 - 2:40 pm          James Yang, Ph.D. “StrategicPartnership for Success in Biologics
2:40 - 3:15 pm           Lynn Yang, MBA, Sequoia Capital “Sequoia China HealthcareInvestment Strategy”
3:15 - 3:50 pm           COFFEE BREAK AND VENDOR SHOW
SESSION III - CFDA Regulatory reform and Innovation for the benefit ofPatients           
3:50 - 4:25 pm           Jason Fisherman, M.D.(TBD)
4:25 - 5:00 pm           XinYu Weng, Ph.D; MBA. “Overview onCFDA Drug Regulatory Reform”    
5:00 - 5:35 pm           Carmen Bozic, M.D. SVP GlobalDevelop. “Innovations in Intrathecal Antisense Oligonucleotide Therapy forNeurological Diseases”
5:35 - 6:00 pm          Closing Remarks and Networking
Registration:
Link: http://caba-annualmeeting-2017.eventdove.com
也可点击文末“阅读原文”或长按以下图片提取二维码直达注册页面。
同写意论坛第59期活动